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8 SUMMARY 
1 SUMMARY 
Bacterial pneumonia is one of the leading causes of death worldwide. Streptococcus 
pneumoniae, the most frequently isolated pathogen from clinical pneumonia samples is 
responsible for 19% death of children below 5 years based on a report from World Health 
Organization. Despite the availability of different vaccines, Streptococcus pneumoniae 
remains the most common pathogen responsible for bacterial pneumonia throughout the world 
and emergence of antibiotic resistance has occurred. Thus, there is high medical need to 
establish new adjunctive therapeutic strategies for treatment of pneumococcal pneumonia.  
In pneumonia, the tight control of the inflammatory response and the maintenance of tissue 
integrity are imperative for the protection of lung function and disease outcome. Severe 
pneumococcal pneumonia is accompanied by massive lung inflammation and bears the risk of 
deleterious respiratory failure as well as of systemic spread of the invading pathogens. 
Therefore, the innate immune response has to be on one side robust, rapid, and highly 
efficient to kill the pathogens but on the other side, it also has to be tightly controlled to 
prevent excessive tissue damage caused by pathogens and the host response itself. Neutrophils 
belong to the class of myeloid cells and forms an important component of this innate immune 
system against bacterial infections. Krüppel-like factor 4 (KLF4) has been reported to not 
only play a role in differentiation of cells of the immune system but also in mediating 
inflammatory signals in the host cells during infection in different cell types such as 
endothelial-, epithelial cells and cells of the innate and adaptive immunity. Taking into 
account that neutrophils are one of the most important regulators of innate immunity during 
pneumococcal pneumonia and that KLF4 has an important role in the neutrophil function 
during bacterial infection, the hypothesis was tested  about the role of KLF4 in neutrophil 
function during S. pneumoniae induced infection in a mice model. 
This study is the first time, which shows myeloid KLF4 has an impact on pneumococcal 
pneumonia outcome and regulates the inflammation associated with bacterial pneumonia in 
vivo in mice. The results presented in the work show that the transcription factor KLF4 is 
induced in human and mice neutrophils during pneumococcal pneumonia. The induction of 
KLF4 is time and dose dependent. Additionally, the expression of myeloid KLF4 is regulated 
by the autolysis of S. pneumoniae but is not mediated via Toll-like receptor (TLR) 2, TLR4 or 
TLR9.  
Studies using a mouse pneumonia model showed that myeloid KLF4 exhibits a pro-
inflammatory phenotype. Mice with KLF4 knockout (KO) or KLF4-/- in myeloid cells had 
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higher bacterial load in their lungs, blood and spleen in comparison to wildtype (WT) or 
KLF4+/+ mice. Although there was less pro-inflammatory cytokine (such as TNF-α, IL-1β and 
KC) production in the broncho-alveolar lavage fluid (BALF) and plasma of KLF4-/- mice yet 
there no differences in cell recruitment in the BALF of the KLF4-/- and KLF4+/+ mice. There 
was however less cell recruitment in the blood of KLF4-/- mice in comparison to KLF4+/+ 
mice. Additionally, an increased vascular permeability associated with perivascular edema 
and pleuritis was seen during Streptococcus pneumoniae-induced infection in KLF4-/- mice, 
which also reached earlier the human endpoints than the KLF4+/+ mice. 
Taken together, myeloid KLF4 has a pro-inflammatory nature as a result of which KLF4-/- 
mice has a higher bacterial load with respect to KLF4+/+ after infection with S. pneumoniae. 
The higher bacterial load is because of the less cytokine production by the myeloid cells and 
this higher concentration of bacteria disrupts the lung architecture and consequently causes 
faster progression of the disease of the KLF4-/- mice.  
The results point out how KLF4 can modulate the immune functions orchestrated by the 
myeloid cells during pneumococcal pneumonia and this could help us develop host directed 
therapeutic options during bacterial pneumonia. 
Keywords:  
Krüppel-like factor 4, neutrophils, pneumonia mouse model, Streptococcus pneumoniae  
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ZUSSAMMENFASSUNG 
Bakterielle Pneumonien sind weltweit eine der häufigsten Todesursachen. Basierend auf 
einem Bericht der Weltgesundheitsorganisation ist Streptococcus pneumoniae der am 
häufigsten in klinischen Proben nachgewiesene Erreger und zu 19% für den Tod von Kindern 
unter 5 Jahren verantwortlich. Obgleich mehrere Impfungen verfügbar sind, stellen 
Pneumokokken weltweit nach wie vor den häufigsten Erreger der Pneumonie dar und treten 
vermehrt Antibiotikaresistenzen auf. Daher besteht eine hoher medizinischer Bedarf für die 
Entwicklung neuer adjunktiver Therapiestrategien zur Behandlung der 
Pneumokokkenpneumonie. 
In der Pneumonie sind eine präzise Kontrolle der Immunantwort und die Gewährleistung der 
Gewebeintegrität zwingend für den Erhalt der Lungenfunktion und einen positiven 
Krankheitsverlauf. Schwere Pneumokokken Pneumonien werden begleitet von massiven 
Entzündungsreaktionen in der Lunge und bergen das Risiko lebensbedrohlicher 
Atemstörungen sowie einer systemischen Ausbreitung des eingedrungenen Erregers. Deshalb 
muss die angeborene Immunantwort einerseits robust, schnell und hocheffizient das Pathogen 
ausschalten, andererseits aber so kontrolliert ablaufen, dass übermäßige Gewebeschädigungen 
durch den Erreger und die Immunantwort selbst vermieden werden. Neutrophile Granulozyten 
gehören zur Klasse der myeloiden Zellen und sind eine wichtige Komponente der 
angeborenen Immunität gegen bakterielle Infektionen. Krüppel-like factor 4 (KLF4) spielt 
dabei nicht nur eine Rolle in der Differenzierung der Zellen des Immunsystems, sondern auch 
während der Infektion bei der Vermittlung inflammatorischer Signale in den Wirtszellen wie 
Endothel- und Epithelzellen sowie Zellen der angeborenen und erworbenen Immunität. 
Aufgrund der herausragenden Rolle von Neutrophilen Granulozyten als Regulatoren 
angeborener Immunität und KLF4 als wichtigem Faktor in der Regulierung von Neutrophilen 
im Kontext bakterieller Infektionen wurde die Rolle von KLF4 in Neutrophilen im S. 
pneumoniae Maus-Infektionsmodel untersucht.  
Diese Studie zeigt zum ersten Mal in vivo in mäusen, dass myeloides KLF4 Einfluss auf den 
Krankheitsverlauf hat und die mit einer bakteriellen Pneumonie einhergehende 
Entzündungsreaktion reguliert. Die hier aufgeführten Ergebnisse demonstrieren, dass der 
Transkriptionsfaktor KLF4 während einer Pneumokokken Pneumonie in humanen und 
murinen neutrophilen Granulozyten induziert wird. Diese Induktion ist Zeit- und 
Dosisabhängig. Außerdem wird die Expression von myeloidem KLF4 durch die Autolyse von 
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S. pneumoniae reguliert, aber nicht über Toll-like Rezeptor 2 (TLR2), TLR4 oder TLR9 
vermittelt. 
Studien in einem Maus-Pneumonie Modell zeigen, dass myeloides KLF4 einen 
proinflammatorischen Phänotyp bewirkt. Mäuse mit einem KLF4 knockout (KO) oder KLF4-/- 
in myeloiden Zellen haben im Vergleich zu Wildtyp (WT) oder KLF4+/+ Mäusen eine höhere 
Bakterienlast in Lunge, Blut und Milz. Obwohl die Produktion pro-inflammatorischer 
Zytokine (wie TNF-α, IL-1β und KC) in der bronchoalveolären Lavageflüssigkeit (BALF) 
und im Plasma von KLF4-/- Mäusen geringer war, gab es keine Unterschiede bei der 
Zellrekrutierung in der BALF von KLF4-/- und KLF4+/+ Mäusen. Allerdings war die 
Zellrekrutierung im Blut der KLF4-/- Mäuse geringer als bei den KLF4+/+ Mäusen. Außerdem 
wurde eine erhöhte vaskuläre Permeabilität verbunden mit perivaskulären Ödemen und 
Pleuritis bei KLF4-/- Mäusen während der S. pneumoniae-induzierten Infektion beobachtet. 
Diese Mäuse erreichten auch eher die humanen Endpunkte als die vergleichbaren KLF4+/+ 
Mäuse. 
Zusammengefasst zeigte myeloides KLF4 einen pro-inflammatorischen Charakter, wodurch 
KLF4-/- Mäuse nach Infektion mit S. pneumoniae eine höhere Bakterienlast im Vergleich zu 
KLF4+/+ Mäusen hatten. Die höhere Bakterienlast resultierte aus der geringeren 
Zytokinproduktion der Myeloidzellen, die höhere Bakterienkonzentration zerstörte die 
Struktur des Lungengewebes und führte so zu einem progressiveren Krankheitsverlauf in 
KLF4-/- Mäusen.  
Die Erkenntnis, dass KLF4 die Immunfunktionen der Myeloidzellen während der 
Pneumokokken Pneumonie moduliert kann womöglich helfen, wirtsspezifische Therapien in 
der bakteriellen Pneumonie zu entwickeln. 
Schlagwörter:  
Krüppel-like factor 4, murines Pneumoniemodell, Neutrophile, Streptococcus 
pneumoniae 
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3 INTRODUCTION 
3.1 The human respiratory system  
Respiration is a process by which oxygen is provided to the tissues in return for carbon 
dioxide. The human respiratory system consists of two parts. The upper respiratory 
conducting zone and the lower respiratory exchange zone. The upper conducting zone, 
responsible for the conduction of air to the lower exchange zone, consists mainly of the 
trachea, bronchi, bronchioles and the terminal bronchioles. The inspired air passes through the 
nasal passage, pharynx, larynx, and is warmed before it reaches the exchange zone. The 
exchange zone mainly consists of the respiratory bronchioles, alveolar ducts and alveoli. The 
air at the end points of the respiratory system, the alveoli, causes O2 to enter the blood from 
the inspired air while CO2 goes in the opposite direction. The blood vessel supplying blood to 
the alveoli and facilitating the blood exchange are the pulmonary capillaries which originates 
from the pulmonary artery and merges again to form the pulmonary vein. The air and blood 
interface at the alveoli is separated by distance 0.5µm due to the presence of the alveolar 
epithelium and the capillary endothelium. The alveolar epithelial cells are of two types-type I 
cells, which are responsible for gaseous exchange and the type II cells, which produces the 
surfactant responsible for reducing the surface tension. Multiple division of the respiratory 
tract massively increases the cross-sectional area thus facilitating gaseous exchange. In 
humans there are 23 divisions between the trachea and the alveolar sacs of which, the first 
sixteen divisions is responsible for air conduction only while the last seven divisions is 
responsible for the gaseous exchange1,2.  
 
3.2  Infections of the respiratory system 
Infections of the upper respiratory system include epiglottitis, laryngitis, laryngotracheitis, 
nasopharyngitis, pharyngitis, rhinitis, sinusitis and tracheitis3. The infection and the respective 
inflammed area is given in table 1. The infections of the upper respiratory system are mostly 
viral origin with the exception of laryngotracheitis, epiglottitis and pharyngitis that are also 
caused by Haemophilus influenzae (H. influenzae) type b and Group-A β-hemolytic 
streptococci4. These diseases are mostly self-limiting in nature. 
 
Table 1: Inflammation areas of upper respiratory tract infections. 
Name of the infection Main area(s) affected  
epiglottitis larynx 
laryngitis larynx 
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laryngotracheitis larynx, trachea 
nasopharyngitis pharynx, nose 
pharyngitis pharynx, tonsils 
rhinitis nasal mucosa 
sinusitis paranasal sinuses  
tracheitis trachea 
 
Lung infections are one of the major burden for the society5. Bronchitis, bronchiolitis and 
pneumonia are the main infections of the lower respiratory system. Inflammation of the 
bronchial tree is defined as bronchitis and bronchiolitis. With the inflammation of the 
bronchial tree, there is edema and excessive secretion within the bronchioles. Bronchitis is 
caused by bacterial infection in combination with environmental factors such as smoking 
while, bronchiolitis is caused by respiratory syncytial virus. Bacterial infections are the most 
common cause of lower respiratory system4. Of the different bacterial infections, bacterial 
pneumonia is one of the leading causes of death not only in developing countries but also in 
developed countries. A World Health Organization (WHO) organization report states that 
19% of all deaths of children below five years of age is caused by pneumonia6. Streptococcus 
pneumoniae (S. pneumoniae) is the most frequently isolated pathogen responsible for 
bacterial pneumonia7,8,9. 
 
3.3 Streptococcus pneumoniae 
S. pneumoniae was first isolated in 1880s by Louis Pasteur and George Miller Sternberg10,11. 
S. pneumoniae belongs to the family Streptococcaceae and is of genus Streptococcus. It is a 
gram positive coccus, normally forming diplococci given that the division of the bacterium 
occurs at a single axis12. The bacterium can be observed in small chains or in pairs. It is α-
hemolytic, catalase negative and non-spore forming encapsulated bacterium. Characteristic 
colonies of S. pneumoniae are given in Fig.1. 
 
Fig. 1 Characteristic colonies of S. pneumoniae. 
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The α-hemolysis is an important identification for these facultative anaerobic pneumococci. 
Since it is catalase negative, the pneumococcal H2O2 changes the colour of the blood agar 
plates from red to green, indicating a transition of the hemoglobin to methemoglobin. Since it 
is facultative anaerobic, the α-hemolysis, the identification parameter of pneumococci is only 
possible if oxygen is present in the environment in which the bacteria is growing. However 
since the pneumococci is phylogenetically related to (viridans) streptococci, the α-hemolytic 
colonies have to be further confirmed with other tests. Other identification parameters include 
the optochin test and bile solubility test. Given that, other α-hemolytic streptococci are 
resistant to optochin (ethylhydrocupreine hydrochloride) while S. pneumoniae is sensitive to 
it, optochin tests are widely used to identify pneumococci. Similarly, with the bile solubility 
test, S. pneumoniae is bile (sodium deoxycholate) soluble whereas other other α-hemolytic 
streptococcal species are bile resistant13. Ideally, the identification of S. pneumoniae should be 
done by molecular biology methods such as by means of 16S rRNA14. The normal diagnostic 
procedure given by the centre of disease control and prevention (CDC), United States of 
America (USA) is given in the flowchart (Fig. 2). 
 
 
Fig. 2 Scheme for identification of S. pneumoniae. 
Typical flowchart used in the detection of S. pneumoniae. The main test include α-hemolytic colonies on blood 
agar plates, gram staining, catalase test, optochin test and bile solubility test. The figure has been adapted from 
the CDC, USA13. Y= Yes, N=No. 
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3.3.1 Virulence factors of S. pneumoniae 
Various virulence factors are responsible for the pathogenicity of S. pneumoniae. The 
following discussion is about the various virulence factors, which are mostly present on its 
surface as given and adapted in Fig. 315.  
 
 
Fig. 3 The multi-faceted virulence factor of S. pneumoniae.  
The various virulence factors of S. pneumoniae include the capsule, cell wall containing lipoteichoic acid (LTA) 
and teichoic acid (TA), choline-binding proteins such as pneumococcal surface protein (Psp) A and PspC, 
divalent metal ion binding lipoproteins such as pneumococcal surface antigen A (PsaA), pneumococcal iron 
acquisition A (PiaA) and pneumococcal iron uptake A (PiuA). Additional virulence factors include covalently 
linked proteins to the bacterial cell wall by a carboxy (C) terminal sortase (LPXTG; where X = any amino acid) 
motif such as neuraminidase. Other enzymatic virulence factors include hyaluronate lyase (Hyl), autolysin 
(LytA), pneumococcal adhesion and virulence A (PavA), pneumolysin (Ply) and enolase (Eno). 
  
3.3.1.1 Capsule 
The outermost layer of S. pneumoniae is its capsule. The capsule is normally 200-400 nm in 
thick and reports have suggested about 90 different types of structure of this capsule16,17. The 
capsule prevents the pneumococci from phagocytosis, complement deposition on the bacterial 
surface and reduces the chances of pneumococci from being trapped in the neutrophil 
extracellular traps (NETs)15,18,19. An interesting phenomenon is the regulation of capsule 
production by the S. pneumoniae. Previous reports have suggested that the pneumococci 
produce less capsular polysaccharide when it comes in close contact with the respiratory 
epithelial cells20. 
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3.3.1.2 Cell wall associated components 
Lipoteichoic acid (LTA) and teichoic acid (TA) are important cell wall components that are 
recognized by the host cells. TLR2 has been reported for the recognition of these cell wall 
components21. Mice lacking TLR2 has been described to show delayed bacterial clearance22. 
Literature review also suggest that LTA induce cytokine response from human mononuclear 
phagocytes21. Important characteristics of pneumococci and diseases (see below) can be 
induced in animal models by application of these cell wall components23.  
 
3.3.1.3 Surface proteins 
The cell wall surface proteins of S. pneumoniae can be classified into three major groups: 
choline-binding proteins, divalent metal ion binding lipoproteins and covalently linked 
proteins to the bacterial cell wall by a carboxy (C) terminal sortase (LPXTG; where X = any 
amino acid) motif. 
Of the 10-15 choline binding proteins produced by S. pneumoniae24, the three main proteins 
include pneumococcal surface protein (Psp) A, PspC and autolysin (LytA). The three 
structural domain containing PspA is thought to prevent complement binding on the bacterial 
surface due to its high electronegative characteristics25. Previous publication have reported 
about how expression of PspA can prevent the bactericidal effect of apolactoferrin, given that 
PspA binds to the iron transporter lactoferrin26,27. PspC binds to the polymeric 
immunoglobulin (Ig) receptor that is responsible for the transport of secretory IgA. This 
interaction with the immunoglobulin receptor promotes pneumococcal adherence28,29. A 
report by Iannelli et al. have stated that PspC mutant pneumococci is much less virulent30. By 
binding with factor H, PspC also prevents the activation of alternate complement activation15. 
Pneumococcal autolysin (LytA) represent an amidase that cleaves N-acetylmuramoyl-L-
alanine of the peptidoglycan present in the pneumococcal cell wall31. With the lysis of the cell 
wall, the virulence of cell wall is mediated by the release of Ply. Previous literature observed 
that LytA mutant S. pneumoniae was less virulent in a mouse pneumonia model32. 
The divalent metal ion binding lipoproteins are of various types and around 42-45 of them are 
encoded by the pneumococci24. The lipoproteins, which act as important virulence factors, 
include pneumococcal surface antigen A (PsaA), pneumococcal iron acquisition A (PiaA) and 
pneumococcal iron uptake A (PiuA). PsaA is a component of the ATP- binding cassette 
(ABC) which helps in manganese transport and thereby promotes pneumococcal 
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adherence33,34,35. PiaA and PiuA, as the name suggests are important components of the iron 
uptake system in the pneumococci. Previous reports have seen though a single mutation of 
either PiaA or PiuA was responsible for less virulence; however, double mutant pneumococci 
lacking the PiaA and PiuA, the virulence was much more reduced36. 
One of the most important virulence protein anchored by the LPXTG motif include 
neuraminidase24. S. pneumoniae encodes three neuraminidases genes, namely nanA, nanB and 
nanC37. This enzyme aid in the adhesion of the pneumococci to the epithelial cells by cleaving 
terminal sialic acid from glycoproteins, present on the host cell surface38. 
 
3.3.1.4 Pneumolysin 
Pneumolysin (Ply) is a 52 kDa cytoplasmic toxin released by S. pneumoniae after autolysis of 
the cell wall. Ply facilitates the survival of the pneumococci in the upper and lower respiratory 
tract39,40. Ply remains as a monomer before forming oligomers which subsequently helps the 
pneumococci not only in inhibiting ciliary beating on epithelial cells but also in reducing 
respiratory bursts41,42. Previous reports have also suggested that the virulence factor Ply is 
required for the bacteria to spread from the lungs into the blood39,40,43,44. Ply have also been 
reported to have cell modulatory and compliment activation activity by which it adds to the 
virulence caused by the pneumococci45,46. Additionally, Ply has been reported to be 
responsible for induction of cytokine such as interleukin (IL)-1β in human lung tissue and 
mononuclear cells47,48. 
 
3.3.2 Diseases caused by S. pneumoniae 
S. pneumoniae is responsible for various diseases. These mainly include sinusitis, otitis 
media, bacterial meningitis and pneumonia. The details of the main diseases is being 
described in brief in this section  
 
3.3.2.1  Sinusitis 
Inflammation of the sinuses and nasal passage is termed as sinusitis. Sinusitis can be either 
acute or chronic in nature. To determine whether the sinusitis is acute or chronic depends on 
the symptoms such as headache, pain over the sinuses, nasal discharge, daytime cough, which 
increases during the night and occasional fever. Over 60% of the cases of acute sinusitis is 
caused by S. pneumoniae and H influenzae12. 
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3.3.2.2 Otitis media 
An infection of the middle ear, otitis media can generally be classified as acute, chronic and 
serous. Acute otitis media in the first three months of life is caused by S. pneumoniae in 35-
40% of the cases12. Common symptoms of the acute otitis media include fever, irritability, 
and inflammation of the tympanic membrane.  
 
3.3.2.3  Meningitis 
Acute purulent meningitis is caused by S. pneumoniae. Other bacterial causative agents 
include H. influenzae type b, Neisseria meningitides. Typical symptoms of bacterial 
meningitis include fever, neural dysfunction and high neutrophil count in the cerebral spinal 
fluid12. The rate of mortality associated with pneumococcal meningitis can be between 47-
53%49. Even the survivors from pneumococcal meningitis suffer from neurological 
complications in comparison to other meningitis50. 
 
3.3.3 Pneumococcal pneumonia 
Pneumococcal pneumonia is one of the leading cause of death of worldwide. S. pneumoniae is 
the most common causative agent responsible for Community acquired pneumonia (CAP). 
Around 60-70% of bacterial CAP reported to be caused by pneumococci51. Data from the 
German Network for Community Acquired Pneumonia (CAPNETZ) has suggested as S. 
pneumoniae as the main causative agent of pneumonia with 80% of all the cases being 
admitted to the hospital7. While in some European and worldwide meta-analysis reports have 
stated that incidence of S. pneumoniae induced CAP varies between 19.3% and 27.3% 
respectively52,53. In spite of the variations in the reported data, S. pneumoniae remains the 
most common pathogen responsible for CAP. The common clinical symptoms include 
shortness of breath, tachypnea, high fever, pleuritic chest pain and huge amount of purulent 
sputum54. Pneumonia is type of severe inflammatory disease marked by increase cytokine 
levels in blood and also in lung tissue (see below)55,56. There are around 2 million deaths of 
children below 5 years of age which may be due to the high inflammation associated with the 
disease. A WHO report by Rudan et al., stated that pneumonia is one of the largest cause of 
death in children below 5 years of age in all the WHO zones, namely; Americas region 
(AMR), African region (AFR), European region (EUR), Eastern Mediterranean region 
(EMR), South East Asian region (SEAR) and West Pacific region (WPR) as given in Fig.46. 
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Fig. 4 Distribution of death of children below 5 years of age due to pneumonia and other causes in all the WHO 
zones.  
Pneumonia being one of the highest cause of death of children below 5 years of age. Americas region (AMR): 
12%, African region (AFR): 21%, European region (EUR): 12%, Eastern Mediterranean region (EMR): 21%, 
South East Asian region (SEAR): 19% and West Pacific region (WPR): 13%. The figure has been adapted from 
Rudan at al6. 
 
3.4  Emergence of multi drug resistant (MDR) S. pneumoniae 
and present vaccination strategies to prevent 
pneumococcal pneumonia 
The emergence of MDR S. pneumoniae is increasing throughout the world especially with 
respect to macrolides and β-lactams. There have also been reports with fluoroquinolone 
resistance57. The emergence of resistance of S. pneumoniae to these group of antibiotics have 
been reported due to their wide spread improper  use58. The emergence of resistance has led to 
increased mortality, morbidity and economical burden59. The mechanism of resistance 
reported to be of various causes. The macrolide resistance is because of the ribosomal 
methylase that dimethylates the target site of the macrolides-23S rRNA60. Additionally, 
macrolide resistance is because of the macrolide efflux pump61. Regarding the β-lactam 
resistance, it is reported about the alteration of penicillin binding proteins (PBPs) that reduced 
the affinity to β-lactams62. Given that the target of fluoroquinolones is mainly bacterial type II 
topoisomerase, mutation in the topoisomerase is responsible for resistance against 
fluoroquinolones63.  
Two types of vaccines are currently in use: the polysaccharide vaccine containing 23 different 
serotypes previously used in clinical scenario. However, the main disadvantage of this 
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polysaccharide vaccine is it cannot protect the host against pneumococcal infection. It can 
however reduce the chances of bacteremia64. The other vaccine that is presently in use is the 
pneumococcal conjugate vaccines (PCV). This vaccine better known as PCV-7 as it contains 
seven different types of pneumococcal polysaccharide (4, 6B, 9V, 14, 18C, 19F and 23F) that 
are most frequently isolated during pediatric infections. Though the PCV-7 seems to be 
promising, but there have been reports of invasive pneumococcal disease due to the serotypes 
not covered by the PCV-765. Advancement of vaccination strategy led to the introduction of 
PCV-13 vaccine, which contains thirteen different serotypes of the pneumococcal capsule, 
however the vaccine effectiveness of PCV-13 against serotype 3 (the same serotype used in 
my in vivo project, see table 12) remains questionable66. Overall, the emergence of antibiotic 
resistance and availability of principally useful, but still insufficient vaccines, results in high 
medical need for the generation of adjunctive therapies by better understanding of the 
pathogenesis of S. pneumoniae-induced inflammation 
 
3.5 The innate immune system 
The body needs immune responses to protect itself from infections and invading pathogens. 
The immune system can be broadly classified into the cells of the innate immune system 
(relevant to this thesis) and the cells of the adaptive immune system. The difference between 
the innate immunity and adaptive immunity is that innate immune system is instantly ready 
for the host defense as soon as the host is attacked by the pathogen, i.e. they do not need 
previous exposure to the pathogens. On the other hand, the adaptive immunity in most of the 
times is initiated after few days of exposure of the cells to the antigens within the host. The 
innate immune system consists of physical barriers, which are the body’s first line of defense, 
e.g. skin or also of chemical barriers like acid pH. Cells of the innate immune system include 
granulocytes (eosinophils, basophils and neutrophils), monocytes, macrophages, natural killer 
cells and the mast cells. The macrophages along with the neutrophils are the cells mainly  
responsible for phagocytosis (see below, 3.5.1). Additionally, mast cells (like the neutrophils) 
contain various type of granules which when released due to stimulation, adds to the local 
inflammation. Certain cells such as DCs are responsible for linking the innate immunity with 
the adaptive immunity. The adaptive immunity consists of the T cells and B cells. T cells can 
be of two types, CD4 T cells, which regulate the adaptive immune responses, and CD8 T 
cells, after developing into cytotoxic cells can kill cells infected with the microbes. B cells are 
responsible for secreting antibodies67,68. 
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3.5.1 Neutrophils 
Neutrophils, the major immune cells during inflammation, are produced from myeloid 
precursors in the bone marrow by a process called granulopoesis. Once produced, which is 
under the control of granulocyte colony stimulating factor (G-CSF)69, the neutrophils are 
subjected to multi-step maturation process. The steps of maturation include from myeloblast 
to promyelocyte followed by myelocyte, which further matures to form metamyelocyte to 
band cell and finally the polymorphonuclear leukocytes (PMNs)70. During maturation, the 
neutrophil attain three type of granules (an important characteristic of mature neutrophils) 
which contains pro-inflammatory proteins. The total number of proteins in the granules is 
greater than 70071.The content of these granules vary from mice to human, for example the 
primary azurophilic granules in human contain defensins which are absent in mice72. The 
number of circulating neutrophils also vary between mice and human: in mice it is 10-25% of 
circulating leukocytes while it is 50-70% in human circulating leukocytes73,74.  
Various modes of defense strategies have been developed by the neutrophils to sense bacteria 
and in turn evoke an antibacterial response. The recognition of bacterial components by the 
innate immune system is discussed in a different section (see below, 3.5.2). Neutrophil 
recruitment at the site of infection, known as neutrophil extravasation involves the following 
steps: tethering, rolling, adhesion, crawling and transmigration. Inflammatory mediators such 
as cytokines and chemokines gradient (released by the tissue resident leukocytes after 
recognizing the microbe) mediate such changes by an induction of adhesion molecules such 
as E-selectin which in turn starts the process of neutrophil tethering75,76,77. Once the 
neutrophils reach the site of infection, they have various ways for being the antimicrobial 
effector. These primarily include phagocytosis and NETs or release of granule components. 
Phagocytosis is a process where particles having a size greater than 0.5µm (such as bacteria) 
are engulfed by the cells. Neutrophils are key phagocytes. The process of phagocytosis is a 
complex process, which begins with the pathogen binding to the cell surface of the phagocyte. 
With the binding of the pathogen on the cell surface, there is an induction of rearrangement of 
actin cytoskeleton within the phagocyte. As a result, the phagocyte progressively engulfs the 
pathogen and forms a vacuole known as phagosome. This phagosome fuses with the 
lysosome, which digest the microbe. The process of phagocytosis is faster if the cells are pre-
activated or in the presence of IgG antibodies or by the complement system78,79,80. NETs 
formation includes the release of chromatin DNA and granules into the extracellular space81. 
The main function of the NETs is to trap the pathogen. A previous study has shown that 
blocking of NET formation aggravated dissemination of the bacteria (Escherichia (E.) coli) to 
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the distant organs82. Other than the chromatin DNA and the histones, there are various 
proteins, which form important part of the NET. These proteins also have antibacterial effects. 
Examples of these proteins which not only forms part of the NET but also has different 
antimicrobial properties include: lactoferrin which inhibit iron uptake by the pathogens, 
cathelicidins or its cleaved product LL-37 which disrupts the bacterial membrane and are also 
pro-inflammatory mediators75,78,83. Additionally, neutrophils interact with other cells of the 
immune system to orchestrate to the host defense against the microbes and can modulate the 
adaptive immune system. Various reports have suggested that the neutrophils can suppress T 
cell proliferation and activate splenic B cells84,85,86. There also exists a positive feedback loop 
mechanism between the neutrophils and the T helper 17 (Th17) cells, whereby Th17 increases 
neutrophil recruitment by release of Interleukin (IL) – 17. The recruited neutrophils in turn 
recruit Th17 cells via release of different chemokines
87.  
Given that lung contains a population of mature neutrophils88, these neutrophils play an 
important role in the host defense against S. pneumoniae infection. Report have suggested as 
neutrophils being the main phagocytes in an acutely inflamed lung during pneumococcal 
pneumonia89. The phagocytic ability of neutrophil during bacterial pneumonia is dependent 
on the production of proteases which kills the ingested bacteria90. Additionally neutrophils 
also produce reactive oxygen species (ROS) for elimination of S. pneumoniae. Selected 
depletion of neutrophils have also shown that the host is not able to clear the bacterial burden 
of S. pneumoniae91,92. However, one such report suggest that S. pneumoniae, though can be 
trapped in NETs, but production of endonuclease by S. pneumoniae helps in the degradation 
of the NETs and in turn causes the evasion of pneumococci from the lungs into the blood93. 
Additionally, S. pneumoniae not only can evade NETs but also it has developed various ways 
to detoxify the ROS produced by the neutrophils for killing it. S. pneumoniae can produce 
NADPH oxidase, thiol peroxidase, superoxide dismutase and alkyl hydroperoxidase for 
clearing ROS94. 
 
3.5.2 Recognition of the invading bacteria 
Cells of the innate immune system, which include the neutrophils and macrophages, 
recognize the pathogen related structure known as pathogen associated molecular patterns 
(PAMPs). 
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3.5.2.1 Pattern recognition receptors (PRRs) 
The recognition of these PAMPs by the cells of the innate immune system is done by the 
pattern recognition receptors (PRRs). PRRs can be of different types: Toll-like receptors 
(TLRs), Nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), c-type 
lectin receptors (CLRs) and retinoic acid-inducible gene-I (RIG-I)-like receptors (RLRs) and 
others. Given that TLRs have one of the most important role in the recognition in S. 
pneumoniae, it will discussed in a different section (3.5.2.2). NOD1 and NOD2 are the two 
main members of the NLRs. NOD1 recognizes the specific structures of the peptidoglycan of 
gram negative bacteria, NOD2 recognizes muramyl dipeptide , an important component of the 
peptidoglycan found in all gram positive and gram negative bacteria95,96. While NOD2 is 
responsible for recognition of bacteria such as S. pneumoniae and Mycobacterium (M.) 
tuberculosis, NOD1 recognizes bacteria such E. coli, Pseudomonas aeruginosa, H. 
influenzae97. Normally with the activation of NLRs, it leads to production of cytokines (see 
below) which contributes to the host defense98,99.  
CLRs recognizes the carbohydrates through the carbohydrate recognition domain (CRDs) or 
through the C-type lectin-like domain (CTLD) for recognition of non-carbohydrate ligands100. 
Of the 17 groups of CLRs, the mannose receptor (MR) has been identified in the recognition 
of bacteria such as S. pneumoniae, Klebsiella pneumoniae, M. tuberculosis101. Activation of 
the CLRs lead to phagocytosis, activation of respiratory bursts and production of mediators of 
inflammation102. 
The RLRs consists of three main members, which include the RIG-I, melanoma differentiated 
associated gene5 (MDA5) and laboratory of genetics and physiology2 (LGP2). The RLRs are 
mostly responsible for recognition of viral RNA103,104.  
3.5.2.2  Toll-like receptors (TLRs) 
Toll-like receptors are mainly transmembrane receptors that consists of an extracellular 
domain and cytosolic domain. The extracellular domain contains leucine-rich repeats (LRRs) 
that are used in the recognition of PAMPs96. Till date 13 TLRs have been identified in mice 
while there are 10 members of the human TLR family105. The TLRs are either located on the 
plasma membrane such as TLR1, 2, 4, 5, 6, 11 or intracellular vesicles such as TLR3, 7, 8, 9. 
Components of the cell wall such as TA and LTA are recognized by TLR221. TLR2 
heterodimerizes with TLR1 or TLR6 and can recognize a wide range of microbe-associated 
molecular patterns (MAMPs) and PAMPs106. TLR4 is important for the recognition of LPS, 
which is a major component present in the gram negative bacteria105. Additionally, TLR4 may 
also be responsible for the recognition of Ply after the autolysis of pneumococci107. Lamina 
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propria DCs (LPDCs) of the small intestine express TLR5 which recognizes the flagellin, an 
important component of the bacterial flagella108. This recognition of LPDCs promotes the 
differentiation of naive B cells into IgA producing plasma cells109. 
TLRs localized internally are responsible for detection of nucleic acid. TLR3 and 7 is mainly 
responsible for detection of viral components such as RNA110,111. TLR8 recognizes RNA from 
human immunodeficiency virus (HIV)112. TLR9 recognizes the bacterial DNA containing 
unmethylated 2’-deoxyribo cytidine–phosphate–guanosine (CpG)113. S. pneumoniae is 
recognized by the innate immune system by various PRRs such as TLR2, TLR4 and TLR9. 
Additionally, NOD2 is also responsible for the recognition of S. pneumoniae components 
within the cytosol105. 
3.5.3  Downstream pathways of the PRRs 
Various downstream signaling pathway are involved after the activation of the PRRs (namely 
the NLRs, RLRs and TLRs) which contributes to the host defense96,109,114. The regulation of 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and mitogen activated 
protein kinases (MAPK) by the PRRs will be discussed here as it is important for the thesis. 
Activation of the MAPK pathway involves three adaptor molecules: p38, extracellular signal-
related kinases1/2 (ERK 1/2) and c-jun N-terminal kinases (JNKs). TLRs evoke biological 
responses through the adaptor molecules. On such adapter molecule is myeloid differentiation 
primary response 88 (MyD88). MyD88 in turn recruits and forms a complex with other 
adapter molecules such as IL-1 receptor-associated kinases (IRAKs). The activated IRAKs 
interact with tumor necrosis factor receptor-associated factor (TRAF) -6. This TRAF-6 then 
interacts with transforming Growth Factor β-activated Kinase 1 (TAK1), TAK1 binding 
protein (TAB) 1, TAB2/3 complex that is the upstream regulator of MAPK. Once activated 
the MAPK pathway is responsible for regulating the transcription of various inflammatory 
genes115,116,117. 
The TLRs via the MyD88-dependent or the independent pathway may activate NF-κB108,118. 
The activation of NF-κB pathway is a multi-step process. Like the MAPK pathway, the 
adaptor molecule MyD88 after interaction with TRAF-6 and sequentially with TAK1, TAB1, 
TAB2/3 complex causes the phosphorylation of inhibitor of κB alpha (IκBα). When the NF-
κB pathway is not activated, the IκBα remains bound to other members of the NF-κB family: 
RelA (p65) and p50. After its phosphorylation, IκBα is subjected to proteasomal degradation. 
The p65-p50 heterodimer then translocates to the nucleus where it control the production of 
inflammatory genes such as cytokines and chemokines119. 
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3.5.4 Cytokines and chemokines 
Small secretory proteins known as cytokines and chemokines regulate immune responses in 
the body. The cytokines can be divided into four different classes. The classification is based 
on the type of immune response induced by the cytokine which are as follows: cytotoxic, 
humoral, cell-mediated or allergic120. In this section, the different types of cytokines and 
chemokines, which are important for this thesis will be discussed. 
Tumor necrosis factor or TNF are of two types - TNF-α produced by neutrophils, 
macrophages, natural killer cells and TNF-β which is a lymphocyte derived necrosis factor. 
TNF-α is a heterodimer produced as a 26 kDa protein121. This protein is transported thereafter 
to the cell surface via the RER and the Golgi complex122. At the plasma membrane, TNF-α 
forms non-covalent trimers123,124 and is cleaved by TNF-α converting enzyme (TACE) to 
form a 17 kDa soluble form of TNF-α125. Trimers of this soluble form of TNF-α binds to 
specific TNF receptors (TNFRs) –I/II and internalized to produce the pro-inflammatory 
signaling such as IL-12126. Literature review have suggested that TLR2 and 4 are responsible 
for the induction of TNF-α production and this TNF-α induces e.g. the expression of adhesion 
molecules such as E-selectin, intracellular adhesion molecule (ICAM)-1, vascular cell 
adhesion molecule (VCAM)-1 to increase the influx of granulocytes into the site of 
inflammation120. Additionally, TNF-α has also been found to play role in the adaptive 
immunity as literature review suggest that it is important for the production of B cell-
attracting chemokine-1 and secondary lymphoid tissue chemokine127. TNF-α has been 
reported to protect the host during pneumococcal infection128,129. 
IL-1 family consists of eleven members of which IL-1β is the most potent pro-inflammatory 
cytokine. Stimulation of NLRs and TLRs induces the production of IL-1β from various cell 
types such as neutrophils, macrophages, monocytes and hepatocytes130,131,132. IL-1β is 
produced as precursor, which subsequently is cleaved by the IL-1 converting enzyme 
(ICE)133. The active IL-1β binds to the IL-1 receptors (IL-1R) 1 or 2 and this in turn activates 
the MyD88 signaling pathway, which further controls the NF-κB and MAPK pathways. Like 
the TNF-α, IL-1β upregulates E-selectin, ICAM-1, VCAM-1 for neutrophil recruitment and 
activation of T-lymphocytes119,120.  
IL-10 is a potent anti-inflammatory cytokine produced by lung epithelial cells, T cells, B cells 
and by macrophages. The production of IL-10 has been reported to be dependent on the NF-
κB pathway regulation by TLRs and NLRs. Given its anti-inflammatory nature, it reduces the 
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inflammation by inhibiting production of TNF-α, IL-1β, IL-6, and IL-8 in mononuclear 
phagocytes120,134,135,136.  
Chemokines are small proteins having three to four conserved cysteine residues. Their 
average molecular weight varies between 8-12 kDa and until date, 44 chemokines have been 
identified in the human genome137. These 44 different chemokines can subdivided into four 
different families: C-X-C, C-C, C, CX3C based on the position of the cysteine residues at the 
N-terminus. The C-X-C has two cysteine residues separated by an amino acid (X = amino 
acid), the C-C subfamily has two cysteine residues side by side, the C subfamily has only one 
cysteine residue and the CX3C has three amino acids between the cysteine residues (X3 = 3 
variable amino acids)138,139. The chemokines bind to G-protein coupled receptors to activate 
leukocytes for an immune response140. Additional functions of the chemokines include 
cytokine expression of CD4+ T cells and differentiation of this T cells into Th1 cells141. 
Previous reports have suggested that important neutrophil genes such as keratinocyte derived 
chemokine (KC, the murine homolog of IL-8 in humans142,143) contains NF-κB binding sites 
in their 5’ untranslated region144. Neutrophils are released from the bone marrow into the 
peripheral circulation in response to infection. This release of neutrophils from the bone 
marrow into the circulation is under the control of KC where KC binds to CXC chemokine 
receptor 2 for the egress of neutrophils into the circulation145. The released neutrophils are 
important for the eradication of pneumococci by means of phagocytosis (see 3.5.1) 
Reports have also suggested that severe progression in CAP is associated with high levels of 
cytokines such as TNF-α, IL-1, IL-6, IL-8, IL-10, IL-12146,147,148.  
 
3.6  Krüppel-like factor (KLFs) 
Krüppel–like factors (KLFs) are zinc finger containing transcription factors in which the word 
“Krüppel” gets its name due to its homology to Drosophila melanogaster Krüppel protein. 
Loss of Krüppel in the fruit fly leads to a cripple (German: Krüppel) appearance of the 
larvae149. KLFs are involved in the regulation of inflammatory response, tissue homeostasis 
and regeneration in different cell types as well as various human diseases150,151,152.  
Till date seventeen KLFs have been identified with a recent prediction for the 18th KLF. 
These 17 KLFs can be subdivided into 3 groups based on their physiological roles- Group 1 
includes KLF3, KLF8 and KLF12 while KLFs 1,2,4,5,6,7 fall under group 2 and Group 3 
comprises KLFs 9,10,11,13,14,16 depending on their activation or repression activity while 
the activity of KLF15 and KLF17 remains unclear152. Given the role of KLF4 in 
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pathophysiology of lung diseases and also its role to in myeloid cells such as macrophages to  
promote inflammation152, it will discussed in details in this thesis. 
3.6.1 Krüppel-like factor 4 
Krüppel like factor 4 (KLF4), was first found in the gut epithelial cells. KLF4, like most of 
the other members of the KLF family has four domains which includes a) N terminus acidic 
activation domain, followed by b) Repressor domain, c) Nuclear localization signal (NLS) 
and finally d) DNA binding domain at the C-terminus which contains Cys2His2 zinc finger 
motifs153,154 as given Fig. 5. This sequence of KLF4 consists of 483 amino acids in mouse and 
has 91% homology to the human KLF4155.  
 
Fig. 5 Structure of the KLF4 transcription factor. 
The KLF4 transcription factor consists of N-terminus acidic activation domain, which is adjacent to the repressor 
domain. The C-terminus domain consists of the zinc fingers (ZF) motifs and the NLS is located between the 
repressor domain and zinc finger motifs, which act as the DNA binding site. The figure has been adapted from 
Ghaleb et al.154. 
3.6.2 Functional role of KLF4 
KLF4 has been documented to have a role in the establishment of the skin barrier. Given that 
it helps in the development of skin barrier, KLF4 KO mice die shortly after birth due to 
spontaneous loss of body fluids156. KLF4 is an important regulator of the cell cycle. Using 
adenoviral overexpression of KLF4 in a cell line, it could be shown that KLF4 is required for 
the transition from G1 to S phase during cell cycle
157. KLF4 achieved a further level of 
recognition for a scientific publication that KLF4 along with octamer binding transcription 
factor 3/4 (Oct3/4), sex determining region Y (SRY) -box2 (Sox2) and v-myc 
myelocytomatosis viral oncogene homologous (c-myc) can transform embryonic or adult 
fibroblast cells into pluripotent stem cells158,159. John B. Gurdon and Shinya Yamanaka were 
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awarded the Nobel Prize for Medicine in 2012 for this finding. Previous report by Hu et al. 
suggested that KLF4 is also down regulated in lung cancer patients, both at RNA level and 
protein level160. Given that it was already established that KLF4 had a role in cell cycle 
regulation, Hu et al. hypothesized that KLF4 mediated its action by regulating p21 and cyclin 
D1. With the activation of p21 and inhibition of cyclin D1, KLF4 induced G1 phase arrest in 
lung cancer cells. A recent study by Khalife et al. has also claimed that KLF4 is a potential 
biomarker for patients with advanced lung cancer, which also partly echoed the findings by 
Hu et al.161. Feinberg et al. had observed that KLF4 influences monocyte differentiation and 
induce macrophage fate162.  
Though various reports suggest about the importance of KLF4 for various cellular functions, 
however there remains discrepancy about the functional role of KLF4 in myeloid cells. 
Recent work by Liao et al. suggests a role of KLF4 in polarization of macrophages. 
Interestingly, they and others observed that KLF4 expression significantly increased in M2 
and decreased in M1 macrophages163,164. However, another study proclaim that KLF4 directs 
macrophages to a more pro-inflammatory M1 phenotype165 further emphasizing that this is an 
area of intense moving research.  
Various reports have suggested that KLF4 can regulate the NF-κB pathway in different cells 
especially during bacterial infection. In a recent publication, it was reported KLF4-deficient 
neutrophils had impaired bacterial killing and reduced cytokine production in vivo during E. 
coli infection. In this report, Shen et al. had also stated that the impact of KLF4 KO during the 
E. coli infection was due to the impaired NF-κB pathway166. KLF4 indeed regulates NF-κB in 
myeloid cells have long been reported when it was shown that KLF4 by interacting with the 
RelA complex to regulate inducible nitric oxide synthase (iNOS), an activation marker of 
macrophages165. Zahlten et al. have also reported how KLF4 can regulate the inflammation 
through the NF-κB pathway, during bacterial infection136,167 (see below, 3.7). 
 
3.7 KLF4 during pneumococcal pneumonia 
Previous studies could show that KLFs could regulate the inflammation associated with 
pneumococcal pneumonia. Literature review shows that the induction of KLF2 in broncho-
epithelial cells was initiated by the recognition of bacterial cell wall components of S. 
pneumoniae by TLR2 as well as NOD2 and the activation of Phosphatidylinositol-4,5-
bisphosphate 3-kinase (Pi3K). A knockdown of KLF2 via KLF2 specific siRNA enhanced the 
S. pneumoniae- induced IL-8 secretion, which leads to the assumption that KLF2 counter-
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regulates the pro-inflammatory immune response168. In two different publications, Zahlten et 
al. have pointed out that the induction of KLF4, which is highly related to KLF2, was 
completely independent of TLR2 or NOD2 and Pi3K activation. The expression of KLF4 in 
bronchial epithelial cells in contrary depends on the pneumococcal autolysin LytA related 
release of bacterial DNA, the activation of the endosomal TLR9 and Src kinases. Once 
expressed KLF4 binds to the il10 and the il8 promotors and leads to the production of the 
anti-inflammatory cytokine IL-10 and the inhibition of the pro-inflammatory chemokine IL-8 
and the cytokine IL-1β whereas IL-6 remains unaffected. The inhibition of IL-8 depends on 
(i) direct protein-protein interaction with the NF-κB subunit p65 and (ii) the recruitment of the 
histone acetylase P300/CBP-associated factor (PCAF) from p65 to KLF4 thereby inhibiting 
the activity of NF-κB136,167.  
Herta et al. investigated the S. pneumoniae-related expression and the function of KLF4 in 
macrophages. Interestingly, strong differences between the induction and function of S. 
pneumoniae-related KLF4 expression in macrophages compared to human lung epithelial 
cells were found. KLF4 induction by pneumococci in macrophages seems to be tightly 
controlled and need the following non-redundant signals: (i) viable bacteria, (ii) LytA-related 
release of bacterial DNA, (iii) direct contact of viable bacteria to the host cells. At least in part 
the effect was mediated by TLR9 and MyD88. Noteworthy, non-CpG DNA (e.g. human, 
mice) which does not activate TLR9 could act as a co-signal in this KLF4 induction. Since 
experiments with cells derived from stimulator of interferon genes (STING)- and apoptosis-
associated speck-like protein containing a CARD (ASC)-, TLR2-, TLR3-, TLR4-, TLR7-, 
NOD2-, Interferon-α/β receptor (IFNAR)-KO mice showed no effect on S. pneumoniae 
related KLF4 induction, the working group is convinced that another hitherto unknown DNA 
receptor participated in this signalling pathway. The results suggest that KLF4 induction in 
macrophages maybe caused by a combination of pathogen-associated molecular pattern-
damage-associated molecular pattern (PAMP-DAMP) signalling and may lead to pro-
inflammatory M1 phenotype169. Fig. 6 gives a summary of the main findings in macrophages. 
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Fig. 6 Pneumococci-dependent induction of KLF4 in macrophages. 
A. The induction of KLF4 expression needs direct contact of viable pneumococci to the bone marrow-derived 
macrophages (BMMs). During replication, the S. pneumoniae autolysin LytA cause the release of bacterial 
DNA. Free DNA is necessary for a) partly KLF4 induction via TLR9/MyD88 and b) a probably yet unknown 
extracellular DNA sensor.  
B. Participation of TLR2, TLR4, NOD2, IFNAR and adaptor proteins such as STING, ASC are not involved in 
the induction of KLF4 in macrophages. Additionally, phagocytosis is also not required though TLR9 is involved 
in the induction of KLF4.The figure is taken from Herta et al.169 under Creative Commons Attribution 4.0 
international license. 
3.8 The LyzMcre system for conditional knockout in mice 
The bacteriophage P1 derived loxP/LyzMcre recombination system was used to create a 
myeloid KLF4-/- lineage on a C57BL/6 mice background. The cre (cyclization recombinase) 
is a site-specific DNA recombinase and can recombine DNA only at specific sites known as 
loxP (locus of X-over P1) sequences. The cre catalyzes the sequences spanning between two 
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loxP sites. As a result, since the cre ‘sits’ between the two loxP sites in the specific cell types 
only (the cells containing the LoxP in their genome) it knockouts the gene of interest in 
specific cells.  
Transgenic mice containing loxP (which have been introduced in the embryonic stem cells by 
homologous recombination) are mated with transgenic mice containing cre gene that can be 
expressed in one specific cell type (LyzMcre for the myeloid cells only). The offspring from 
this mating will result in mice that will have both cre and loxP. As a result, cell specific 
LyzMcre will cause a specific gene knockout (KLF4 in this case) in myeloid cells only. This 
report by Clausen et al. had suggested that there can be a conditional knockout of 83-98% in 
mature macrophages and 100%  in mature neutrophils with the LyzMcre system170. It is 
briefly illustrated in Fig. 7.  
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Fig. 7 The LyzMcre system for conditional gene knockout in mice. 
Mice containing loxP flanked sequence (upper right) was mated with a mice containing cell type specific cre 
recombinase (upper left). The product of mating is a mouse (below) where cre deletes the floxed genomic 
sequences. The deletion of the genomic sequences causes a specific gene knockout of a specific cell type only. 
The figure has been adapted from Bouabe et al.171.  
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4 AIM OF THIS WORK 
Neutrophils are key effector cells of the innate immune system in pneumococcal pneumonia 
and there are contradictory results about the role of KLF4 in the regulation of myeloid cells 
function. In addition, although several reports indicate an up-regulation of KLF4 in S. 
pneumoniae infection in various cell types, however it´s in vivo function in pneumonia is 
unknown. The objective of this work is thus to evaluate the role of KLF4 in neutrophils 
concerning the outcome and the progression of pneumococcal pneumonia in a murine model. 
Therefore, the following research questions were addressed: 
1. Is KLF4 expressed in neutrophils during pneumococcal pneumonia? 
2. What are the virulence factors of Streptococcus pneumoniae that may be responsible for the 
expression of KLF4? 
3. Does the myeloid KLF4-/- regulate the cytokine production of neutrophils in vitro? 
4. Has myeloid KLF4 an impact concerning the cytokine response in the lung and in the blood 
of S. pneumoniae infected mice? 
5. Is there an impact of myeloid KLF4 concerning the recruitment of cell types in the lung and 
blood? 
6. What is the impact of myeloid KLF4 concerning the bacterial clearance in the lung, the 
blood and spleen? 
7. Does the knockout of myeloid KLF4 alter the survival of the mice during S. pneumoniae-
induced pneumonia and sepsis? 
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5 MATERIAL AND METHODS 
5.1 Instruments 
Table 2: Instruments. 
Instruments  Company  Method 
Autoclave  Systec Sterilization of reagents, 
destruction of infected 
materials 
Bio Photometer  Eppendorf Bacterial growth OD values  
Centrifuge  Eppendorf Collection of supernatants 
(ELISA), collection of cell 
lysates (Western blot), 
preparation of bacteria  
FACS Canto-II BD  Quantification of cell 
populations 
FilterMax F5 
Multi-Mode Microplate 
Reader 
Molecular Devices ELISA  
Incubator  Thermo Scientific Grow and maintain cells and 
bacteria 
Laminar Air flow bench Thermo Scientific Cell isolation and bacterial 
infection 
Microscope Olympus Counting cells 
Mini Trans-Blot® Cell Bio-Rad Western blot 
Mini-PROTEAN® Tetra 
handcast system 
Bio-Rad Protein electrophoresis  
Mini-PROTEAN Tetra® 
Vertical Electrophoresis Cell  
Bio-Rad Protein electrophoresis 
Nanodrop 2000 Thermo Scientific DNA amount and purity 
Odyssey Scanner LI-COR Western blot membrane 
visualization 
Photometer BioMate Thermo Scientific Determination of protein 
amount after Bradford 
Polymax 1040 Heidolph Instruments Shaking membrane (Western 
blot) 
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PTC-200 Peltier thermal 
cycler 
MJ research Amplification of DNA/PCR 
PowerPac™ Basic power 
supply 
Bio-Rad Protein/DNA electrophoresis 
/ Western blot 
RCT basic Ika-Labortechnik Magnetic stirrer (Western 
blot) 
Subcell® GT Bio-Rad DNA electrophoresis 
Thermomixer Comfort Eppendorf Heating protein samples to 
95°C  
(protein electrophoresis), 
heating DNA samples 
Vet ABC ™Hematology 
Analyzer 
Scil Quantification of cell 
population 
 
5.2 Consumable supplies 
Table 3: Consumable supplies. 
Supplies Company 
Cannula (diff. sizes) Braun  
Cassettes for histology Carl Roth GmbH 
Cell strainers: 70μm, 100μm  Falcon  
Clear 96-well plate maxisorp Nunc™ 
Columbia agar plate + 5% sheep blood  BD Mikrobiologie 
Cotton stick Applimed SA 
Cuvettes Sarstedt 
K2EDTA vials  Sarstedt  
Eppendorf tubes (diff. sizes) Sarstedt 
FACS tubes Falcon 
Inoculation loop Carl Roth GmbH 
MACS pre-filters: 30μm  Miltenyi Biotec  
MACS Separation columns (LS)  Miltenyi Biotec  
Nitrocellulose hybond membrane GE Healthcare Life Sciences  
PCR tubes: 0.5ml  Sarstedt  
Pipette tips (diff. sizes) Biozym / Sarstedt 
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Seal plate Excel Scientific Inc. 
Serological pipettes (diff. sizes) Falcon 
Syringes: 1ml, 2ml, 10ml  Braun  
Tubes: 15ml, 50ml  Falcon  
Whatman gel blotting paper GE Healthcare Life Sciences 
 
5.3 Chemicals and reagents 
Table 4: Chemicals and reagents. 
Reagent Company 
2-propanol Sigma-Aldrich 
4% paraformaldehyde (PFA) Carl Roth GmbH 
Acrylamide / Bis-Acrylamide, 40%, Ratio 
19:1 
Serva 
Agarose Biozym 
Albumin, from bovine serum Sigma-Aldrich 
Ammonium chloride Sigma-Aldrich 
Ammonium persulfate (APS) Serva 
Ampuwa  Fresenius Kabi 
Bradford Protein Assay Bio-Rad 
Bromophenol blue Sigma-Aldrich 
Potassium hydrogen carbonate Sigma-Aldrich 
Complete™ Protease Inhibitor Cocktail 
Tablet 
Roche  
EDTA Sigma-Aldrich 
EDTA-Na salt Carl Roth GmbH 
Ethanol Merck Millipore 
Glycerol Merck Millipore 
Glycine Merck Millipore 
H2SO4; 95-97% Merck Millipore 
HBSS Gibco 
Heparin Rotexmedica  
  
44  MATERIAL AND METHODS 
 
Ketamin Rotexmedica 
Lysozyme Merck Millipore 
Mutanolysin Sigma-Aldrich 
N-Lauroylsarcosine sodium salt Sigma-Aldrich 
Nonidet® P-40 99% Fluka 
Nucleic acid staining solution Red Safe™ 
Ody Blocking Buffer LI-COR 
PBS Gibco 
Phenol Sigma-Aldrich 
Precision plus Protein™ kaleidoscope Bio-Rad 
Proteinase K Sigma-Aldrich 
RNase 5 prime GmbH 
SDS Serva 
Sodium acetate Carl Roth GmbH 
Sodium chloride Carl Roth GmbH 
Sodium fluoride 99% Sigma-Aldrich 
Sodium orthovanadat 98%  Sigma-Aldrich 
Sodium pyrophosphate  Sigma-Aldrich 
TEMED Serva 
TES Sigma-Aldrich 
Todd-Hewitt Broth  BD Mikrobiologie 
TriDye 100bp DNA ladder New England BioLabs 
Tris base Sigma-Aldrich 
Tris-HCl Sigma-Aldrich 
Triton X-100 Sigma-Aldrich 
Tween-20 Sigma-Aldrich 
Xylazin Rotexmedica 
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Yeast extract Sigma-Aldrich 
β-mercaptoethanol  Sigma-Aldrich 
 
5.4 Antibodies 
5.4.1 Antibodies for Western blot 
Table 5: Antibodies for Western blot. 
Antibody Host Type Company 
Anti-GKLF rabbit primary Santa Cruz 
Biotechnologie 
Anti-β-Actin goat primary Santa Cruz 
Biotechnologie 
Anti-rabbit 
conjugated Cy 5.5 
goat secondary Rockland 
Anti-goat conjugated 
IRDye 800 
donkey secondary Rockland 
 
5.4.2 Antibodies for FACS 
Table 6: Antibodies for FACS. 
Antibody Company 
CD11c (N418) Cy5 Biolegend 
CD11b (M1/70) PE‐Cy7 eBioscience™ 
F4/80 (BM8) PE eBioscience™ 
CD45 (30‐F11) FITC BD 
Ly6G (1A8) PerCP-Cy5.5 BD 
Ly6C (HK1.4) BV510 Biolegend 
MHC-II (M6/114.15.2) AF700 eBioscience™ 
Siglec F (E50‐2440) BV421 BD 
aCD16/32 BD 
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5.5 Antibiotics for selection 
Table 7: Antibiotics. 
Antibiotic Company 
Kanamycin Sigma Aldrich 
 
5.6 Stimulants 
Table 8: Stimulants. 
Stimulant Origin Usage Company 
CpG (ODN M362) recombinant TLR9-agonist InvivoGen 
LPS Salmonella 
Minnesota R595 
TLR4-agonist Enzo Lifesciences 
MALP-2 recombinant TLR2-agonist Enzo Lifesciences 
 
5.7 Cell culture medium 
Table 9: Cell culture medium. 
Reagent Company 
RPMI 1640 Gibco 
fetal calf serum GE Healthcare 
L-glutamine Sigma-Aldrich 
 
5.8 Genotyping Primers 
Table 10: Genotyping primers. 
Primer name Sequence Company 
Lys olMR 3066 Mutant 5’-CCC AGA AAT GCC 
AGA TTA CG-3’ 
Metabion international AG 
Lys olMR 3067 Common  5’-CTT GGG CTG CCA 
GAA TTT CTC-3’ 
Metabion international AG 
Lys olMR 3068 WT  5’-TTA CAG TCG GCC 
AGG CTG AC-3’ 
Metabion international AG 
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KLF4 exon1 5’-CTG GGC CCA CAT 
TAA TGA-3’ 
Metabion international AG 
KLF4 exon2 5’-AGT CTG ACA TGG 
CTG TCA GCG-3’ 
Metabion international AG 
KLF4 intron 5’-CAG AGC CGT TCT 
GCC TGT TTT-3’ 
Metabion international AG 
 
5.9  Kits 
Table 11: Commercial kits. 
Kits Company 
EasySep™ direct human neutrophil isolation kit  STEMCELL™ technologies 
Mouse anti-Ly-6G Microbead kit  Miltenyi Biotec 
Mouse albumin ELISA Biomol 
Mouse IL-1β ELISA  eBioscience™ 
Mouse TNF-α ELISA  eBioscience™ 
Mouse IL-10 ELISA  eBioscience™  
Mouse KC ELISA  R&D Systems  
 
5.10 Pneumococci strains 
Table 12: Streptococcus pneumoniae strains. 
Strain capsule LytA Type of 
experiment 
D39 wild type yes yes In vitro 
D39Δcps no yes In vitro 
R6x  no yes In vitro 
R6xΔlytA no no In vitro 
NCTC 7978 yes yes In vivo 
 
  
48  MATERIAL AND METHODS 
 
5.11 Methods 
5.11.1 In vitro experiments 
5.11.1.1 Storage and culture of Streptococcus pneumoniae 
Different strains of pneumococci were stored at -80°C for long-term storage. Initially, the 
pneumococci were plated on 5% sheep blood containing Columbia blood agar plates and 
supplemented with antibiotics (50mg/ml kanamycin for D39Δcps and R6xΔlytA). These 
plates were incubated at 37°C with 5% CO2 for 12h. After this incubation, the colonies were 
again transferred to new blood agar plates and incubated. Thereafter, the colonies were 
suspended in 1ml of cryoconservation medium (30g/l Todd-Hewitt broth with 0.5% yeast 
extract and 20% glycerol, pH=7.8 ± 0.2). 
For infection of the cells, the bacterial strains were plated on 5% sheep blood Columbia agar 
plates, supplemented with the antibiotics if necessary for the mutant strains. The plates were 
incubated overnight at 37°C with 5% CO2. The next day, single bacterial colonies were 
incubated in pre-warmed THY and allowed to grow until the OD600 reached 0.2-0.4 at 37
°C 
with 5% CO2. The bacteria containing THY was then centrifuged at 1800g for 10 minutes. 
The supernatant was discarded to get the bacterial pellets, which were then suspended in 
RPMI 1640 with 2% FCS and 1% glutamine to reach a concentration of 1x109 CFU/ml. This 
concentration was further diluted via serial dilution to get the required concentration for the 
infection of cells.  
5.11.1.2 Isolation of R6x DNA 
R6x strain was plated on Columbia blood agar plates and incubated overnight at 37°C, 5% 
CO2. The next day, 2-3 colonies were incubated in pre-warmed THY and the bacteria was 
allowed to grow until the OD600 value reached 0.6. The THY containing bacteria was then 
centrifuged at 1800g for 10 minutes at 4°C. The bacterial pellets were resuspended in 6ml 
TES. For lysis of the cells, 1ml of lysozyme (5mg/ml in TES) was added followed by addition 
of 100µl of Mutanolysin (1mg/ml in Tris-HCl pH 7.5). This mixture was incubated at 37°C 
for 1h. 100µl of RNase (5mg/ml in TES with 15 minutes pretreatment at 75°C to inactivate 
DNase) was added and again incubated at 37°C for 15 minutes. 100µl Proteinase K was added 
to it and kept at 30°C for 30 minutes. This was followed by further addition of 500µl 10% N-
Lauroylsarcosine sodium salt (in 250mM EDTA) and allowed to react for 1h at 37°C. 2ml 
phenol was added followed by shaking and centrifugation at 3023g for 10 minutes. The 
supernatant was collected and precipitated with 1/10vol 3M sodium acetate and 1vol 2-
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propanol. Pellets of DNA will be seen separating out. If pellets of DNA were not observed, 2-
propanol was further added. The DNA pellets were suspended in 1ml 70% ethanol and 
centrifuged at 4487g for 5 minutes. After centrifugation, the DNA pellets were suspended in 
Tris-EDTA buffer (1M Tris-HCl, 0.5M EDTA, pH 8.0) and the concentration was measured 
using Nanodrop. 
5.11.1.3 Isolation of neutrophils from human blood  
Blood was taken from healthy subjects with their prior consent. Around 10ml was collected in 
K2EDTA tubes for each set of experiments. Neutrophils were then isolated by negative 
selection using the EasySep™ (STEMCELL™ technologies). The cells were then resuspended 
in RPMI 1640 with 2% FCS and 1% glutamine before stimulation with bacteria, bacterial 
DNA or TLR agonist. Cells numbers were determined by Neubauer chamber. 
5.11.1.4 Isolation of neutrophils from mouse bone marrow and whole 
blood 
Animal experiments were done based on FELASA guidelines. All in vitro experiments using 
cells of mice were approved by the host institution (Charité - Universitätmedizin Berlin) and 
governmental (LAGeSo Berlin, registration no.: T0087/15). All experiments were performed 
under i.p. anesthesia of ketamine and xylazine followed by cervical dislocation or 
exsanguinations via the vena cava caudalis. 
For the isolation of neutrophils from bone marrow, the extremities were removed from the 
mice. Subsequently, the connecting tissues attached to the bones were removed. The bones 
were sterilized in 70% ethanol for 5 minutes and then immersed in RPMI 1640. The bones 
were crushed carefully using a mortar without hurting the cells. The RPMI 1640 containing 
cell suspension was passed through a 70µm cell strainer followed by a centrifugation at 300g 
for 10 minutes at 4°C. After centrifugation at 300g for 10 minutes at 4°C, the cells were 
resuspended in 1-2ml MACS buffer (0.5% BSA in 2mM EDTA dissolved PBS, pH 7.2) and 
passed through a 30µm MACS pre-filter. The neutrophils were then isolated using the MACS 
mouse anti-Ly-6G kit by means of positive selection. The isolated neutrophils, after 
determining the cell number in microscope, was re-suspended in RPMI 1640 with 2% FCS, 
1% glutamine and used for experiment immediately. Cell numbers were determined by 
Neubauer chamber. 
For isolation of neutrophils from whole blood, blood was collected from the vena cava 
caudalis after application of 50µl of heparin into it. Blood from at least 10 mice in each group 
was pulled down to get enough cells for one independent experiment. After the blood was 
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collected in 50ml tubes, red blood cells were lysed using red blood cell (RBC) lysis buffer 
(155mM NH4Cl, 10mM KHCO3, 10nM EDTA-Na; pH 7.4). The RBC lysis was repeated 
again to get rid of all the red blood cells and then the neutrophils were isolated using the 
MACS mouse anti-Ly-6G kit by means of positive selection. The other fraction of the cells 
(except for the RBC) was also collected for further analysis. The cells were resuspended with 
in RPMI 1640 supplemented with 2% FCS and 1% glutamine. Cell numbers were determined 
by Neubauer chamber. 
5.11.1.5 Genotyping and PCR 
For genotyping of mice, ear biopsies were obtained from the mice. These biopsies were 
incubated overnight in lysis buffer (1M Tris-HCl, 0.5M EDTA, 5M NaCl, 10% SDS in 
distilled water) with Proteinase K (10mg/ml). The incubation was done in thermo-block at 
54°C. Next day, the tubes were flipped upside down to mix properly and then centrifuged at 
3824g for 10 minutes. After centrifugation, the supernatant was collected and 500µl 2-
propanol was added, mixing the component well. Subsequently, a centrifugation at 15294g for 
5 minutes was done with this mixture. Following the removal of the supernatant, 500µl 70% 
ethanol was added to wash the DNA pellet. After adding ethanol, it was again centrifuged at 
17949g for 5 minutes and the supernatant was carefully discarded. The DNA pellets were air 
dried and dissolved in 10µl nuclease free water. The concentration of the DNA was measured 
thereafter using a Nanodrop.  
For the PCR amplification of LyzMcre, 50ng DNA was added to components as given in 
table 13. For each DNA sample, a pair of PCR mixture was prepared, namely-mutant and 
wildtype. 
Table 13: Components of the PCR mixture for LyzMcre.  
Mutant Wildtype 
Component Volume Component  Volume 
10x DreamTaq green 
buffer  
5µl 10x DreamTaq green 
buffer  
5µl 
dNTPs 1µl dNTPs 1µl 
DreamTaq DNA 
polymerase 
0.5µl DreamTaq DNA 
polymerase 
0.5µl 
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Primer Lys olMR 
3066 Mutant 
0.3µl Primer Lys olMR 
3068 WT  
0.3µl 
Primer Lys olMR 
3067 Common  
0.3µl Primer Lys olMR 
3067 Common  
0.3µl 
Water 37.9µl Water 37.9µl 
DNA 5µl DNA 5µl 
Total Volume 50µl Total Volume 50µl 
 
The PCR cycle was also different for the two sets and is given in table 14 and 15. PCR was 
performed in PTC-200 Peltier thermal cycler. 
Table 14: PCR cycle for mutant probes. 
Cycle name Temperature of the 
cycle (°C) 
Time of each cycle Total number of 
cycles 
Initial denaturation 95 15 minutes 1 
Denaturation 95 30 seconds 40 
Annealing 62 60 seconds 40 
Extension 72 60 seconds 40 
Final extension 72 2 minutes 40 
 
 
Table 15: PCR cycle for wildtype probes. 
Cycle name Temperature of the 
cycle (°C) 
Time of each cycle Total number of 
cycles 
Initial denaturation 95 15 minutes 1 
Denaturation 95 30 seconds 40 
Annealing 67 60 seconds 40 
Extension 72 60 seconds 40 
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Final extension 72 2 minutes 40 
 
The same isolated DNA was also used for flox amplification. For the flox amplification, 50ng 
DNA was mixed with the following components as given in table 16. 
Table 16: Components of PCR mixture for flox. 
Components Volume 
10x DreamTaq green buffer  5µl 
MgCl2 2µl 
dNTPs 1µl 
DreamTaq DNA polymerase 0.5µl 
Primer exon1 0.3µl 
Primer exon2 0.3µl 
Primer intron 0.3µl 
Water  35.6µl 
DNA 5µl 
Total volume 50µl 
  
PCR amplification for flox was done in PTC-200 Peltier thermal cycler and the cycle 
conditions are given in table 17. 
Table 17: PCR cycle conditions for flox amplification. 
Cycle name Temperature of the 
cycle (°C) 
Time of each cycle Total number of 
cycles 
Initial denaturation 95 15 minutes 1 
Denaturation 95 30 seconds 32 
Annealing 60 30 seconds 32 
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Extension 72 60 seconds 32 
Final extension 72 7 minutes 32 
 
For the gel electrophoresis, 20µl PCR samples were run on 1% agarose gel with 0.04% Red 
Safe™ nucleic staining solution for 45 minutes at 70 volts. For the LyzMcre genotyping, the 
wildtype PCR probe and mutant PCR probe were loaded in adjacent pockets for the respective 
mice. Along with the samples, a reference DNA ladder (TriDye 100bp DNA ladder, New 
England BioLabs) was also loaded. The bands were visualized with ultraviolet light and 
documented with a camera. The description of the flox genotyping for the representative 
samples (1-6) in Fig. 8A are given in table 18. The description of the LyzMcre genotyping for 
the representative samples (1-7) in Fig. 8B are given in table 19. 
 
Fig. 8 Genotyping of mice for in vitro and in vivo experiments. 
Ear biopsies of mice were used for DNA extraction and in turn for flox and LyzMcre genotyping. All the mice 
used in our study are flox++ so only band ~300 bp long was visible as given in the representative gel picture 
(Fig. 8A). For the LyzMcre genotyping, each mice have a pair of PCR samples, known as wildtype and mutant. 
The length of wildtype band is ~350bp and the mutant band is ~700 bp as given in the representative gel picture 
(Fig. 8B).  
Table 18: Evaluation for flox++. 
Sample No. KLF4 flox 
(~300bp) 
Mice type 
1 yes Flox++ 
2 yes Flox++ 
3 yes Flox++ 
4 yes Flox++ 
5 yes Flox++ 
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6 yes Flox++ 
 
Table 19: Screening of mice for LyzMcre. 
Sample No. Wildtype (~350bp) Mutant(~700 bp) Mice type 
1 yes yes KLF4 heterozygote 
or KLF+/- 
2 yes yes KLF+/- 
3 yes yes KLF+/- 
4 no yes KLF4-/- 
5 yes no KLF4+/+ 
6 yes no KLF4+/+ 
7 no yes KLF4-/- 
 
5.11.1.6 Infection of cells  
Isolated neutrophils from human blood or mouse bone marrow/blood were always stimulated 
in 1.5-2ml tubes. To infect the cells, RPMI 1640 medium containing 2% FCS and 1% 
glutamine with bacterial suspension was added to cells (1x106 CFU/ml – 1x108 CFU/ml for 
MOI1-100 respectively). For the control cells, only RPMI 1640 medium with 2% FCS and 
1% glutamine was added. For the stimulation with R6x DNA, the concentration was 5µg/ml. 
For the stimulation with the TLR agonists, MALP-2 was used at a concentration of 0.05ng/µl, 
LPS at a concentration of 0.1ng/µl and CpG at a concentration of 10ng/µl. 
For the Western blot experiments, the stimulation was done for 3h and 6h. For the ELISA 
experiments, the stimulation was done for 16h. 
5.11.1.7 Phagocytosis assay by neutrophils 
Streptococcus pneumoniae strains were grown in THY and resuspended in HBSS with Ca2+ 
and Mg2+ at a concentration of 1x108 CFU/ml. 10µl of this bacterial suspension (equivalent to 
1x106 CFU/ml) was taken with 40µl mouse serum of the respective strain and opsonized for 
30 minutes at 37°C. To this 100µl of RPMI 1640 containing neutrophils isolated from mice 
blood (concentration of cells 1x104) was added. Thereafter, it was incubated at 37°C for 1h. 
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After this, 50µl of lysis buffer (20µl of 10% Triton X-100 + 30µl HBSS with Ca2+ and Mg2+) 
was added and kept for 10 minutes at 37°C. This was plated in serial dilutions in Columbia 
blood agar plates and viable bacterial colonies were counted the next day. 
5.11.1.8 Western blot 
5.11.1.8.1 Extraction of protein 
At the respective time points after the infection, the tubes were centrifuged at 1700g for 3 
minutes at 4°C. The supernatants were discarded and 40µl of lysis buffer was added to pellet. 
Thereafter it was stored at -20°C overnight. The composition of the lysis buffer is given in 
table 20. The next day, the tubes were thawed on ice and centrifuged at 15294g for 10 minutes 
at 4°C. The supernatants were collected and transferred to new tubes and kept at -20°C for 
storage. 
Table 20: Composition of lysis buffer for Western blot. 
Buffer Composition 
Phosphoprotein wash buffer 5ml sodiumorthovanadat 98% (Stock 
solution 200mM) 
50ml sodium pyrophosphate (Stock solution 
150mM) 
50ml sodium fluoride 99% (Stock solution 
1M) 
395ml distilled water 
 
Phosphoprotein lysis buffer 100μl Tris-HCl, pH 7.4 (Stock solution 
500mM) 
50μl (v/v) Nonidet® P-40 (Stock solution 
20%) 
40μl Complete™ Protease Inhibitor Cocktail 
  
810μl phosphoprotein wash buffer 
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5.11.1.8.2 Estimation of total protein 
Total protein content in the samples were measured using the Bio-Rad protein assay following 
the manufacturer’s protocol. The OD595 was measured using spectrophotometer. 
5.11.1.8.3 Preparation of samples for electrophoresis 
Laemmli buffer was added to the samples in the ratio of 1:4.The samples were heated to 95°C 
for 5 minutes in thermo-block. The samples were cooled on ice before loading them into the 
gel for electrophoresis. The composition of the laemmli buffer is given in table 21. 
Table 21: Composition of the Laemmli buffer. 
Buffer Composition 
Laemmli buffer 1ml Tris-HCl, pH 6.8 (500mM) 
0.8ml glycerol 
1.6ml SDS  
0.4ml bromophenolblue 
0.4ml β-mercaptoethanol 
5.0ml distilled water 
 
5.11.1.8.4 SDS-PAGE and immunoblot 
In order to resolve the protein in the samples based on their size, the samples were run on 
sodium dodecylsulfate polyacrylamide gel (SDS-PAGE). 40µg of protein was loaded into 
each pocket of 10% SDS-PAGE, which is composed of the upper stacking and lower 
resolving gel. The electrophoresis for separation was done at 100 volts (constant voltage) for 
1.5-2h in running buffer. Along with the samples was also loaded a reference protein marker 
(Precision plus Protein™ kaleidoscope, Bio-Rad). The composition of stacking gel, resolving 
gel and running buffer is given in table 22. 
For Western blot, the proteins were wet transferred to a nitrocellulose membrane at 100 volts 
(constant voltage), for 1h under cool conditions. The membranes were incubated with Ody 
blocking buffer for 2h at room temperature to prevent nonspecific binding of the antibodies to 
other proteins. The membranes were incubated overnight with anti-GKLF antibody at 4°C 
with shaking so that the antibody spread uniformly throughout the membrane. The next day, 
the membranes were washed 2 times with PBST (1x PBS + 0.01% Tween-20) followed by 1 
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time wash with PBS. The membranes were incubated with the secondary fluorescent 
conjugated antibody for 1h at room temperature. The membrane was again subjected to 
similar washing-2 times with PBST (1x PBS+0.01% Tween-20) followed by once wash with 
PBS. The membranes were scanned using odyssey scanner and the KLF4 band was quantified 
using Image studio 5.2. 
After scanning, the membrane was incubated with anti-β-Actin antibody for 1h at room 
temperature to check the loading control. Following a similar wash with PBST and PBS, the 
membranes were incubated with secondary fluorescent conjugated antibody for 30 minutes at 
room temperature. The membranes were finally washed with PBST and PBS like before, 
scanned and quantified for Actin. The composition of the transfer buffer is given in table 22 
and the antibody dilutions are given in table 23. 
Table 22: Composition of buffers for SDS-PAGE and immunoblotting. 
Buffer/Solution Composition 
Resolving gel (2x) 4.85ml distilled water 
2.5ml Tris-HCl pH 8.8 (stock Solution 
500mM) 
2.5ml Acrylamide/Bis-Acrylamide (40%, 
ratio 19:1) 
100µl 10% SDS 
50µl 10% APS 
5µl TEMED 
Stacking gel(2x) 2.426ml distilled water 
1.0ml Tris-HCl pH 6.8 (stock Solution 1.5M) 
0.534ml Acrylamide/Bis-Acrylamide (40%, 
ratio 19:1) 
40µl 10% SDS 
40µl 10% APS 
10µl TEMED 
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Running Buffer 3g Tris base 
14.4g glycine 
1g SDS 
1000ml distilled water 
Transfer buffer 3g Tris base 
14.4g glycine 
20% methanol 
1000ml distilled water 
 
Table 23: Dilutions of the antibodies used for Western blot. 
Antibody Dilution in odyssey blocking buffer 
Anti-GKLF 1:1000 
Anti-β-Actin 1:1000 
Anti-rabbit conjugated Cy 5.5 1:2000 
Anti-goat conjugated IRDye 800 1:2000 
 
5.11.1.9  Enzyme-linked Immunosorbent Assay (ELISA) 
For the ELISA, the stimulation was done for 16h. At the end of the time point of infection, the 
samples were centrifuged at 300g for 10 minutes at 4°C. The supernatants were collected and 
kept at -20°C for storage. 
All ELISAs were performed according the manufacturer’s instruction (eBioscience™ or R&D 
systems). Maxisorp 96 well plates were used for the analysis and the optical density was 
measured at 450 nm using multi-mode microplate reader (FilterMax F5). A standard curve 
was generated and the results were expressed in pg/ml.  
5.11.2 In vivo experiments 
The local instituition (Charité - Universitätmedizin Berlin) and governmental organization 
(LAGeSo Berlin, registration no.: G0028/16) approved all the in vivo experiments. Female 
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mice with C57BL/6 background, aged 8-11 weeks were kept in individually ventilated cages 
and were provide food and water ad libitum. All experiments were performed under i.p. 
anesthesia of ketamine and xylazine. 
C57BL/6 ERT-Cre+/-/Klf4loxP/loxP mice and C57BL/6 ERT-Cre-/-/Klf4loxP/loxP mice (kind 
gift from Gary K. Owen, University of Virginia, Charlottesville) were mated with B6.129P2-
Lyz2tm1(cre) Ifo mice (Charles River, Sulzfeld, Germany) to generate the KLF4 WT mice or 
KLF4+/+ (C57BL/6 LyzMCre-/-/Klf4loxP/loxP) and KLF4 KO mice or KLF4-/- 
(LyzMcre+/+/Klf4loxP/loxP ). 
 
5.11.2.1 Mouse pneumonia model 
S. pneumoniae (NCTC 7978) was grown in THY. The bacteria were resuspended in PBS 
before infecting the mice. Mice were anesthetized and transnasal infection of 5x105 CFU/ml 
was done for the CFU, ELISA, FACS, histology experiments. A dosage of 5x104 CFU/ml was 
done for the survival experiment as the experiment would continue for 10 days after the 
infection. For both the KLF4-/- and KLF4+/+ mice groups, the control mice were given 
transnasal dosage of PBS. The animals were kept in 12h light/dark cycle and also monitored 
every 12h for clinical symptoms (including temperature and weight) until the end of the 
experiment. The animals were euthanized when their level of pain reached the prescribed 
human end point. 
 
5.11.2.2 CFU measurement in the lung, blood and spleen of infected 
mice 
KLF4-/- and KLF4+/+ mice were sacrificed 24h after infection. The blood was collected from 
the vena cava caudalis and kept in K2EDTA tubes to prevent clotting. The lung and the spleen 
samples were removed from the mice, homogenized in chilled PBS and passed through a 
100µm cell strainer. Serial dilution of the blood, lung and spleen homogenates were made 
with PBST. The samples were plated on 5% sheep blood Columbia blood agar plates and 
incubated at 37°C, 5% CO2 overnight. The colonies were counted the next day. 
 
5.11.2.3 Preparation of Broncho-alveolar lavage fluid (BALF) and 
plasma 
KLF4-/- and KLF4+/+ mice were anesthetized, 24h after infection. Blood was collected from 
the vena cava caudalis and stored in K2EDTA tubes at 4°C. The tubes were then centrifuged 
  
60  MATERIAL AND METHODS 
at 2000g for 10 minutes at 4°C and the supernatant (plasma) was collected and transferred to 
new 1.5ml tubes. For the preparation of BALF, a cannula was inserted into the trachea of the 
mice and the lungs were flushed twice with 800µl of chilled PBS for the collection of BALF. 
 
5.11.2.4  Analysis of cell recruitment in blood and BALF 
Blood was collected from the mice and stored in K2EDTA tubes. The cell population was 
estimated in whole uncoagulated blood using the Scil Vet ABC ™Hematology Analyzer. 
BALF was collected and staining with required antibodies were done. Surface block (given in 
table 24) was added to 100µl of BALF sample in FACS tubes and incubated on ice for 5 
minutes. Thereafter, the surface staining antibody mixture (given in table 25) was added to it 
and incubated for 30 minutes on ice in dark. Subsequently, the FACS tubes were filled up 
with PBS, centrifuged at 425g for 5 minutes at 4°C and the supernatant was discarded. 180µl 
of 1% Paraformaldehyde (PFA) in PBS was added to fix the cells and incubated overnight at 
4°C. The next day, the tubes were filled with FACS buffer (0.2% BSA in PBS) and 
centrifuged at 425g for 5 minutes at 4°C. After discarding the supernatant, the samples were 
resuspended in 100µl FACS buffer and measured in BD Canto-II. The cell populations were 
quantified were using FlowJo version 10.4.2. 
Table 24: Composition of the surface block. 
Antibody Amount in 100µl staining volume (µl)  
aCD16/32 0.5 
FACS buffer 9.5 
Total volume 10 
 
 Table 25: Composition of the surface staining antibodies. 
Antibody (clone) colour Amount in 100µl staining 
volume (µl) 
CD11c (N418)  Cy5 0.4  
CD11b (M1/70)  PE‐Cy7 0.5 
F4/80 (BM8)  PE 0.8 
CD45 (30‐F11)  FITC 0.25 
Ly6G (1A8)  PerCP-Cy5.5 0.5 
Ly6C (HK1.4)  BV510 0.5 
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MHC-II (M6/114.15.2)  AF700 0.15 
Siglec F (E50‐2440)  BV421 0.8 
FACS Buffer     --- 16.1 
Total volume    --- 20 
 
5.11.2.5 Mouse albumin ELISA 
Mouse plasma and BALF was collected as described previously. Samples were diluted as 
given in table 26. Mouse albumin was measured using mouse albumin ELISA kit (BioMol, 
Hamburg, Germany). Different dilutions have been used for different sample types so that the 
OD values are within the detection range of the ELISA kit. The OD values were multiplied by 
their respective dilution factors to get the actual albumin content in the BALF and plasma. For 
the quantification of vascular permeability, the albumin content in the BALF was divided by 
the albumin content in the plasma of the respective mouse and multiplied by 1000 to get 
values greater than 0.00.  
Table 26: Dilution of samples for mouse albumin ELISA. 
Sample  Type of infection Dilution 
BALF PBS 1:1000 
BALF  S.p. 1:10000 
Plasma PBS 1:500000 
Plasma S.p. 1:500000 
 
 
5.11.2.6 Preparation of lungs and other organs for histological analysis 
This part of the study was done in collaboration with Prof. Achim Gruber (Department of 
veterinary pathology, Freie Universität Berlin). The mice were anesthetized 24h post infection 
and the whole lungs were removed carefully along with the trachea and put in the embedding 
cassette (Carl Roth GmbH). Similarly organs such as thymus, heart, spleen, liver, small 
intestine, large intestine, kidneys were also removed and put in embedding cassettes. The 
brain was also removed and put in 50ml tube. All the samples were fixed in 4% PFA pH=7.0 
up to 48h and embedded in paraffin. Multiple sections were cut from the paraffin embedded 
samples and analyzed for histopathology markers172,173,174. Additionally lung samples were 
also stained for S. pneumoniae antibody (as kind gift from Prof. S. Hammerschmidt, Ernst-
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Moritz-Arndt Universität Greiswald) to ascertain the bacterial load in the lung as have been 
previously described175. 
5.11.3 Statistical Analysis 
Statistical analysis was done using GraphPad Prism 6. Mann-Whitney U test was used for 
comparison of two populations. For the analysis of cytokines in vitro, unpaired t-test was 
used. For comparison of populations for more than two groups, one way ANOVA followed 
by Dunn’s multiple comparison test was used. For the survival experiment, Mantel-Cox log 
rank test was performed. Multiple t-test was performed for comparison of the weight and 
temperature between the two groups of the survival experiment. 
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6 RESULTS 
6.1 In vitro 
6.1.1 S. pneumoniae induces KLF4 expression in human neutrophils in a time 
and dose dependent manner but this expression is not dependent on 
TLR2, 4, 9. 
Since we have already seen an increased expression of KLF4 in BMMs during pneumococcal 
pneumonia from previous studies, which had a functional role169, experiments were done to 
see whether neutrophils showed any KLF4 expression during bacterial pneumonia. Human 
neutrophils were isolated from whole blood obtained from healthy individuals. The cells were 
stimulated for 3h (Fig. 9A) and 6h (Fig. 9B-D) with different doses (Multiplicity of Infection 
(MOI) 1, Fig. 9A and B or MOI10, Fig. 9C-D) of Streptococcus pneumoniae. The samples 
were lysed for Western blot analysis for checking the protein expression of KLF4. 
Unstimulated neutrophils (C) did not show any KLF4 expression (Fig. 9A-D). It was 
observed that there was a strong induction of KLF4 in human neutrophils in case of the 
unencapsulated S. pneumoniae strain (R6x). There was significant induction of KLF4 at 
MOI1, both after 3h and 6h stimulation. (Fig. 9A and B respectively). For the wildtype S. 
pneumoniae strain (D39) and the other unencapsulated S. pneumoniae strain (D39∆cps), 
higher MOIs were needed for KLF4 expression (Fig. 9C and D respectively). Neutrophils 
isolated from human blood were also stimulated with TLR ligands. MALP-2 (0.05ng/µl) was 
used as TLR2 ligand, CpG (10ng/µl) as TLR9 agonist while LPS (0.1ng/µl) was used as 
TLR4 ligand for 6h. No induction of KLF4 was seen in human neutrophils after stimulation 
with the TLR-ligands as given in Fig. 9B. 
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Fig. 9 KLF4 is induced in human neutrophils by S. pneumoniae. 
Neutrophils were stimulated for 3h (Fig. 9A) or 6h (Fig. 9B-D) with S. pneumoniae strains R6x (Fig. 9A and B), 
D39 (Fig. 9A-C) and D39Δcps (Fig. 9A, B and D) with different MOIs. Neutrophils were also stimulated with 
TLR2, 4, 9 ligands for 6h (Fig. 9B). The cell lysates were used for Western blot analysis. The membranes were 
incubated with primary antibody overnight (KLF4) as given in the upper panel in Fig. 9A-D. Actin was detected 
on the same membrane as the loading control (lower panel in Fig. 9A-D). The membranes were scanned using 
LI-COR Odyssey scanner and quantification of the membranes (band intensity) was done using image studio 
ver2.0. Fold induction was calculated by the ratio of KLF4 and Actin. The blots shown are representatives from 
three independent experiments. The graphs are shown as Mean ± SD and the results were analyzed with one-way 
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ANOVA followed by Dunn’s multiple comparison test. Statistically significant differences were characterized 
using graphpad prism software, by asterisks as follows: P<0.05 *. 
6.1.2 Pneumococci-induced expression of KLF4 depends on autolysis 
Zahlten et al. and Herta et al. have previously shown that LytA (autolysin) dependent release 
of bacterial DNA was a controlling factor in the induction of KLF4 in epithelial cells and 
macrophages during S. pneumoniae infection167,169. The present experiment was done to see 
whether the induction of KLF4 was also dependent on autolysin like in the other cell types. 
Human neutrophils (Fig. 10A) and neutrophils isolated from the Bone Marrow (BM) of WT 
C57BL/6 mice (Fig. 10B), were stimulated with R6x, the autolysin deficient R6x (R6x∆lytA), 
R6x DNA, and combination of R6x∆lytA and R6x DNA. The stimulation was done for 6h. 
The whole cell lysates were the used for Western blot analysis. The induction of KLF4 due to 
R6x was reduced in the R6x∆lytA. DNA alone was not sufficient to induce KLF4 but the 
KLF4 signal could be partly brought back only when the neutrophils were stimulated with the 
combination of R6x∆lytA and R6x DNA. 
 
Fig. 10 The expression of KLF4 in human and mice neutrophils due to pneumococci depends on autolysis.  
The cell lysates after 6h stimulation was used for Western blot and the membranes were incubated with KLF4 
and Actin antibody sequentially (Fig. 9). It was observed that the induction of KLF4 due to R6x in human 
neutrophils (Fig. 10A) and mice BM-derived neutrophils (Fig. 10B) was reduced and not induced when the cells 
were stimulated with R6x∆lytA and R6x DNA respectively. However, the reduced induction of KLF4 could be 
partly reversed when the combination of R6x∆lytA and R6x DNA was used for stimulation. In all stimulations, a 
MOI1 was used. The control cells (C) are the cells without any stimulation (Fig. 10A and B). The upper panel is 
KLF4 and lower panel is Actin, which is used as the loading control. Blots shown are representatives from three-
six independent experiments in Fig. 10A and from four independent experiments in Fig. 10B. The graphs are 
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shown as Mean ± SD and the results were analyzed with one-way ANOVA followed by Dunn’s multiple 
comparison test. Statistically significant differences were characterized using graphpad prism software, by 
asterisks as follows: P<0.05 * and P< 0.01 **. 
6.1.3 The LyzMcre system has a functional KO in blood derived neutrophils 
but not in BM derived neutrophils 
After the initial screening of mice with genotyping PCR, BM-derived neutrophils and blood 
derived neutrophils were isolated from KLF4+/+ (Fig. 11A, B), KLF4-/- (Fig. 11A, B) and also  
KLF4+/- (only Fig. 11A). The cells were then stimulated for 6h (MOI1) with R6x and the cell 
lysates were used for Western blot analysis. There was hardly any KO in the BM-derived 
neutrophils (Fig. 11A) but a significant knockdown (~90%) of KLF4 in neutrophils isolated 
from blood but not in the other white blood cells (Fig. 11B) as seen in the Western blot data. 
 
Fig. 11 LyzMcre causes a KLF4 KO only in blood derived neutrophils. 
The cell lysates were used for Western blot and incubated with KLF4 antibody, as given in the upper panel. 
Actin used as a loading control is given in the lower panel. Blots shown are representative from three 
independent experiments in neutrophils isolated from the BM and blood (Fig. 11A and B). The graphs are shown 
as Mean ± SD and results were analyzed using one way-ANOVA followed by Dunn’s multiple comparison test 
and P<0.05 * was defined as the level of significance.  
6.1.4 KLF4-/- and KLF4+/+ neutrophils do not show any differences in bacterial 
killing in vitro  
Phagocytosis and killing of bacteria are central important functions of myeloid cells to clear 
bacterial infections. Therefore, it was tested whether KLF4-/- did have any impact in the 
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bacterial killing by neutrophils. Neutrophils isolated from blood of KLF4+/+ and KLF4-/- mice 
were stimulated with S. pneumoniae D39 and R6x for 1h (Fig. 12A and B). In both cases, a 
MOI100 infection was tested. The cells were then plated on blood agar plates in serial 
dilutions, and CFU were counted the next day. However, the neutrophils show their inherent 
bacterial killing activity (~ 1.5 log scales) but there were no differences in bacterial killing by 
neutrophils with respect to KLF4-/-.  
 
Fig. 12 Analysis of the bacterial killing in KLF4-/- neutrophils. 
Fig. 12A and B represent the CFU results of neutrophils stimulated with D39 (A) and R6x (B) respectively from 
three independent experiments. Input C (Input control) are the bacterial dilutions without the neutrophils. The 
graphs are shown as Mean ± SD and the results were analyzed with one-way ANOVA followed by Dunn’s 
multiple comparison test. Statistically significant differences were characterized using graphpad prism software, 
by asterisks as follows: P<0.05 *. 
6.1.5 KLF4-/- neutrophils produce less TNF-α and KC 
Besides their direct killing activity of neutrophils, these cells contribute to the regulation of 
the innate immune response by the liberation of inflammatory mediators119,120. Therefore, the 
effect of KLF4 protein presence or absence on the pneumococci-related liberation of such 
mediators was tested. 16h after stimulation with S. pneumoniae D39, neutrophils with KLF4-/- 
produce significantly less TNF-α (Fig. 13A) and significantly less KC (Fig. 13B). 
Noteworthy, there was no KC measurable in the KLF4-/- neutrophils (under detection limit). 
Since it is now known that there is no knockdown of KLF4 in the other white blood cells (see 
Fig. 11B) these cells were used as a control. Fig. 13C-D shows that there were no differences 
in the cytokine response to S. pneumoniae in the WBCs (excluding neutrophils) indicating a 
specific effect of the KLF4-/- in neutrophils concerning the cytokine response. 
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Fig. 13 KLF4-/- specific alteration of pneumococci induced cytokines in neutrophils. 
The cells after isolation were stimulated with S. pneumoniae D39 for 16h (MOI1). The supernatants were used 
for cytokine measurement. The various cytokine/chemokines levels were measured using commercially available 
ELISA kits following the manufacturer’s instruction. For neutrophils: TNF-α and KC in Fig. 13A and B 
respectively and for WBCs: TNF-α and KC in Fig. 13C and D respectively. The graphs are shown as Mean ± SD 
from three independent experiments and the results were analyzed using unpaired t-test. Statistically significant 
differences were characterized using graphpad prism software, by stars as follows: P< 0.01 **; P<0.0001 ****. 
N.D. = not detectable. 
6.2  In vivo 
6.2.1  Higher bacterial load in lungs, blood, spleen in myeloid KLF4-/- mice, 24h 
post infection  
The above-described in vitro results indicate that KLF4 affects inflammatory mediator 
liberation rather than affecting the pneumococcal killing ability of neutrophils. To investigate 
how these functional alterations influences the bacterial load in vivo, a mouse pneumonia 
model was used. Initially, colony forming unit (CFU) in the lungs, blood and spleen were 
analyzed. In the lungs (Fig. 14A), the KLF4-/- mice had significant higher bacterial load 
(around two log scales) 24h after infection with S. pneumoniae NCTC 7978 than the KLF4+/+ 
mice. KLF4-/- mice also showed significantly higher bacterial load in the blood with respect to 
the KLF4+/+ mice (Fig. 14B, around half log scale).The tendency was similar in the spleen 
  
69 RESULTS 
(Fig. 14C, around 3.5 log scales). The CFU results were further confirmed when the whole 
lung samples, after fixation, were stained with S. pneumoniae antibody and it was found that 
the amount of bacteria in the KLF4-/- mice was 2 times than that of KLF4+/+ mice, 24h post 
infection with NCTC 7978 (Fig. 14D). Similarly, KLF4-/- mice showed significantly higher 
bacterial load in lungs than KLF4+/+ mice, 48h post infection (Fig. 14E, around 4 log scales).  
              
Fig. 14 KLF4-/- myeloid cells leads to higher bacterial load.  
C57BL/6 mice were infected transnasal with 5x10
5 
S. pneumoniae (Strain NCTC 7978) and were sacrificed 24h 
or 48h post infection. The lung, spleen samples (after homogenization in 1x PBS) and blood samples (collected 
in K
2
EDTA tubes) were plated on blood agar plates in serial dilution. The blood agar plates were incubated 
overnight at 37°C, 5% CO
2
. The CFUs were counted the next day. The results are from five mice in each group 
(Fig. 14A, C, and E) and eleven mice in each group (Fig. 14B). For the histopathology analysis, four mice were 
used in each group (Fig. 14D). Each lung section were stained with S. pneumoniae antibody and semi-
quantitatively evaluated under light microscope for positive cells. The results were analyzed by Mann-Whitney 
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U test and statistically significant differences were characterized using graphpad prism software, by asterisks as 
follows: P< 0.05 *; P<0.01 **. N.S. = not significant. 
6.2.2 Lower pro-inflammatory cytokine and higher anti-inflammatory cytokine 
in BALF of myeloid KLF4-/- mice, 24h post infection 
Usually, the measured cytokine levels correspond to the bacterial load in the lung or in the 
blood: the more bacteria, the more cytokine response55,56. Surprisingly, although there were 
more bacteria in KLF4-/- mice compared to the KLF4+/+ mice, there was significantly less 
TNF-α (Fig. 15A), IL-1β (Fig. 15B), KC (Fig. 15C) while significantly more anti-
inflammatory cytokine such as IL-10 (Fig. 15D) in BALF of KLF4-/- mice in comparison to 
KLF4+/+ mice, 24h after infection with S. pneumoniae NCTC 7978. In the PBS treated mice in 
both the KLF4-/- and KLF4+/+ groups, no cytokines could be detected in the BALF.  
 
 
Fig. 15 Analysis of the cytokine levels in the BALF of PBS and S. pneumoniae infected mice.  
Cytokine ELISA was done using commercially available kits to detect the cytokine levels in the BALF. 
C57BL/6 mice were infected transnasal either with 5x105 S. pneumoniae (Strain NCTC 7978) or with PBS and 
were sacrificed 24h post infection and BALF was taken after flushing the lung twice with PBS. The results are 
from six mice in each group and statistics were done by Mann-Whitney U test. P<0.05 * and P<0.01 ** was 
considered as the level of significance. The cytokine levels in the BALF of PBS infected mice in both the groups 
were below the detection limit (N.D. - Not Detectable). 
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6.2.3 Lower pro-inflammatory cytokine and higher anti-inflammatory cytokine 
levels in plasma of myeloid KLF4-/- mice, 24h post infection 
Just like the BALF, KLF4-/- myeloid cells led to production of significantly less pro-
inflammatory cyto-/chemokines (TNF-α, KC and IL-1β in Fig. 16A, B and C respectively) 
and significantly more anti-inflammatory cytokine in the plasma (IL-10 in Fig. 16D) although 
there were much more bacteria in the blood of KLF4-/- mice. No cytokines could be detected 
in the in the PBS treated KLF4-/- and KLF4+/+ mice. 
 
Fig. 16 Analysis of the cytokine levels in the plasma of PBS and S. pneumoniae infected mice.  
Cytokine ELISA was done using commercially available kits to detect the cytokine levels in the blood. C57BL/6 
mice were either infected transnasal with 5x105 S. pneumoniae (Strain NCTC 7978) or with PBS and were 
sacrificed 24h post infection and blood was collected in K2EDTA tubes and these samples were then centrifuged 
for the collection of plasma which was used for further analysis . The results are from six mice in each group for 
the PBS mice (Fig. 16A-D) which were below detection limit (N.D. - Not detectable). For the NCTC 7978 
infected category, eleven mice were used in each of  KLF4+/+ and KLF4-/- group (Fig. 16A-D). Graphs shown are 
analyzed by Mann-Whitney U test and P<0.05 *; P<0.01 ** and P<0.001 *** was considered as the level of 
significance.  
6.2.4 Less neutrophil recruitment in the blood but not in the BALF of KLF4-/- 
mice, 24h post infection 
Given that a lower pro-inflammatory cytokine profile was found in the KLF4-/- mice, it was 
expected to see less cell recruitment in BALF and plasma. Even though there was less 
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neutrophil recruitment in the blood of KLF4-/- mice in comparison to KLF4+/+ mice (Fig. 
17A), there were no differences in neutrophil recruitment between the KLF4-/- and KLF4+/+ 
mice in the BALF (Fig. 17B), 24h after infection with S. pneumoniae NCTC 7978. 
 
Fig. 17 Analysis of cell recruitment in the blood and BALF of PBS and S. pneumoniae infected mice.  
C57BL/6 mice were either infected transnasal with 5x105 S. pneumoniae (Strain NCTC 7978) or with PBS and 
were sacrificed 24h post infection and BALF was taken after flushing the lung twice with PBS. Blood was 
collected in K2EDTA tubes and analyzed using Scil vet abc hematology analyzer (Fig. 17A). BALF samples 
were analyzed using Fluorescence-activated cell sorting (FACS) (Fig. 17B). The results are from at least six 
mice in each group and were analyzed with one-way ANOVA followed by Dunn’s multiple comparison test. 
P<0.05 * was considered as the level of significance. N.S. = not significant. 
6.2.5 Myeloid KLF4-/- led to increased vascular permeability within the lungs 
during pneumococcal pneumonia 
The presence of the bacteria, their released virulence factors (such as Ply) as well the as the 
resulting host innate immune response itself contributes to lung barrier failure with 
deleterious breakdown of the lung gas exchange in severe pneumonia45,176. To assess the 
pulmonary vascular permeability, mouse albumin (MA) ELISA was done with the respective 
BALF and plasma of each mouse to follow the leakage of the albumin molecule as a marker 
of barrier failure from the circulation into the airspace. It was observed that KLF4-/- mice have 
significantly higher vascular permeability (Fig. 18) with respect to KLF4+/+ mice, 24h post 
infection with S. pneumoniae NCTC 7978. In the PBS treated mice, no increase in vascular 
permeability was detected in both groups, 24h post infection. 
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Fig. 18 Myeloid KLF4-/- led to increased vascular permeability during bacterial pneumonia. 
C57BL/6 mice with myeloid KLF4-/- and KLF4+/+ lineage were either infected transnasal with 5x105 S. 
pneumoniae (Strain NCTC 7978) or with PBS and were sacrificed 24h post infection. The quantification of 
vascular permeability was done by the ratio of respective BALF/Plasma ratio and multiplying it with 103. The 
results are shown from six mice in each group and were analyzed by Mann-Whitney U test and statistically 
significant differences were characterized using graphpad prism software, by asterisks as follows: p<0.01 **. 
6.2.6 KLF4-/- mice have more perivascular edema, pleuritis, necrosis and more 
affected lung area, 24h post infection 
KLF4-/- mice showed significantly more perivascular edema (Fig. 19A) and pleuritis (Fig. 
19B) in the whole lung, 24h post infection with S. pneumoniae NCTC 7978. Myeloid KLF4-/- 
mice also showed a higher tendency of necrosis (Fig. 19C) and affected lung area (Fig. 19D) 
24h after infection. Whole lung images were obtained to assess these lung inflammation 
scores. Representative pictures shown for lung perivascular edema (Fig. 19E), pleuritis (Fig. 
19F) and necrosis (Fig. 19I) which were found vividly in KLF4-/- mice 24h post infection with 
S. pnemoniae but absent or comparatively found lesser in KLF4+/+ mice (Fig. 19G and H). 
Representative pictures are also shown for whole lung images for both the KLF4-/- and 
KLF4+/+ mice, PBS and NCTC 7978 infected (Fig. 19J-M). 
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Fig. 19 Analysis of lung inflammation score. 
C57BL/6 mice were infected transnasal either with 5x105 S. pneumoniae (Strain NCTC 7978) or with PBS and 
were sacrificed 24h after the infection and whole lung samples were fixed in 4% PFA for up to 48h. The samples 
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were then stained with Hematoxylin/Eosin for further analysis. The results are shown as Mean ± SD in Fig. 19A-
D (above) are from four mice in each group and were analyzed with one-way ANOVA followed by Dunn’s 
multiple comparison test. Statistical significance was considered as follows: P<0.05 *. (middle) Representative 
pictures of various lung inflammation scores found in KLF4-/- mice (Fig. 19E, F and I) but absent or found to a 
very less extent in KLF4+/+ mice (Fig. 19G, H). In Fig. 19E, KLF4-/- mice infected with NCTC 7978 shows 
perivascular edema (*) at 10x magnification. In Fig. 19F, similarly, KLF4-/- mice shows pleuritis (↑) at 40x 
magnification. In Fig. 19G and H, KLF4+/+ mice infected with NCTC 7978 shows thickening of alveolar 
membranes (*) at 10x and 40x magnification respectively, indicating interstitial pneumonia. In Fig. 19I, KLF4-/- 
mice, 24h after infection with NCTC 7978 shows necrosis of alveolar membrane (#) with neutrophil infiltration 
(*), indicating suppurative bronchopneumonia (*). (below) Whole lung images of PBS treated and NCTC 7978 
infected KLF4-/- and KLF4+/+ mice were obtained as given in representative images for KLF4+/+ PBS (Fig. 19J) 
and NCTC 7978 infected mice (Fig. 19K) and also KLF4-/- PBS (Fig. 19L) and NCTC 7978 mice (Fig. 19M) to 
assess the histopathology associated with the inflammation during pneumococcal pneumonia.  
6.2.7 No impact of myeloid KLF4-/- on other visceral organs, 24h post infection 
We hypothesized that higher bacterial load in the blood of the myeloid KLF4-/- might affect 
other organs in the body. As a result, other organs such as brain, thymus, heart, spleen, liver, 
small intestine, large intestine, kidneys of KLF4-/- and KLF4+/+ mice have also been used for 
histopathological analysis. Intact organ samples from PBS and NCTC 7978 infected from 
both the KLF4-/- and KLF4+/+ mice (n = four in each group of PBS and NCTC 7978), after 
fixation in 4% PFA were stained with hematoxylin and eosin and analyzed for inflammatory 
symptoms. However, no major differences or impact were found between the two groups, 24h 
after infection (data not shown).  
6.2.8 Myeloid KLF4-/- mice show more clinical symptoms of sickness and had 
to be euthanized earlier compared to KLF4+/+ mice 
In the next step, the overall effect of myeloid KLF4 on pneumococcal pneumonia in mice was 
assessed. Experiments were done to investigate the impact of KLF4-/- on the survival of mice 
after infection with 5x104 CFU/ml. The lower dosage was used as the mice were monitored 10 
days post infection to see whether the KLF4 KO had any impact on the overall survival. 
Doehn et al have previously used the same experimental setup where the C57BL/6 mice had 
been treated with Cpl-1, 24h after infection with S. pneumoniae and was monitored over a 
period of 10 days (240h) to assess their survivability177. In Fig. 20A, it is seen KLF4-/- mice 
had to be euthanized earlier and more with respect to KLF4+/+. They generally reached the 
human endpoints within 2.5 to 3.5 days after infection while KLF4+/+ mice between 3 to 5 
days after infection. The weight of both KLF4-/- and KLF4+/+ mice at the beginning of 
experiment were same (Fig. 20B). There were major differences in temperature between 
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KLF4-/- and KLF4+/+ mice (Fig. 20C) but not any differences in their weight over the period 
of 10 days (Fig. 20D). The fall in body temperature in KLF4-/- mice was especially between 2 
- 2.5 days after the infection. Various clinical symptoms, which showed that KLF4-/- mice are 
sicker than the KLF4+/+ mice, are shown in Fig. 20E-J. These clinical symptoms are from 
experiments where the animals have been infected with a higher dosage of NCTC 7978 
(5x105 CFU/ml). In these experiments, the animals had to be monitored up to 48h (end of the 
experiments). Certain clinical symptoms such as accelerated breathing rate (Fig. 20E and F) 
were shown by KLF4-/- mice much earlier (36h time point) with respect to KLF4+/+ mice 
(seen only at 48h time point). This was also observed with the mice reacting to external 
stimuli. KLF4-/- mice started to be less responsive to external stimuli at 36h time point (Fig. 
20G) while the same was observed with KLF4+/+ only at 48h time point (Fig. 20H). In 
addition, KLF4-/- mice always showed much more raised fur be it at 24h or 48h (Fig. 20I and J 
respectively) with respect to KLF4+/+. All the parameters and guideline for these clinical 
symptoms including body weight and temperature are well defined in the LAGeSo proofed 
monitoring sheet. Animals were always sacrificed when their level of pain reached the human 
end points in consultation with department-authorized veterinarian. 
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Fig. 20 Myeloid KLF4-/- mice reach earlier the human end points post infection and shows early and higher 
clinical symptoms of sickness. 
Fig. 20A shows that KLF4-/- mice had to be euthanized earlier compared to KLF4+/+ mice (each group n = ten). 
The weight, temperature and clinical symptoms (such as raised fur, response to external stimuli, movement etc.) 
were monitored every 12h after infection. The mice were euthanized when their level of pain reached the human 
end point in consultation with a department-authorized veterinarian. The result shows the percent of animal 
survival every 12h in each group over the period of 10 days (240h). The graph is analyzed using Log-rank 
(Mantel Cox) test. Statistical significance is defined as P<0.05 *. Fig. 20B shows the weight of individual mice 
in each group along with the mean weight of KLF4-/- and KLF4+/+ at day zero. Fig. 20C, D shows variation in 
body temperature (C) and weight (D) in both groups over the period of 10 days. In Fig. 20C, multiple t-test has 
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been done with the help of graphpad prism software and the statistical significance are given as follows: P<0.05 
* and p = 0.063 #. 
In Fig. 20E-J the clinical symptoms from animals infected with higher dosage were also assessed. KLF4-/- mice 
showed earlier symptoms of accelerated breathing rate at 36h (Fig. 20E, n = five in each group) than KLF4+/+ 
mice which showed only at 48h (Fig. 20F, n = four to five in each group). KLF4-/- mice started to show lower 
responses to external stimuli at 36h (Fig. 20G, n = five in each group) than KLF4+/+ mice which showed at 48h 
(Fig. 20H, n = four to five in each group). Higher scores of KLF4-/- in the graph of reaction to external stimuli 
imply that they are more ‘not’ responsive to external stimuli. KLF4-/- mice showed much more raised fur not 
only at 24h (Fig. 20I, n = seventeen in each group) but also at 48h (Fig. 20J, n = four to five in each group). All 
the graph are shown as Mean ± SD and analyzed using Mann-Whitney U test and P<0.05 * P<0.001 *** was 
considered as the level of significance. N.S. = not significant. 
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7 DISCUSSION 
Bacterial infections are the most prevalent disease in the human lower respiratory tract5. With 
the advent of MDR bacterial strains, treatment of the lower respiratory tract infections has 
become a big challenge91. Bacterial pneumonia is one of leading causes of death worldwide 
and it is most frequently caused by S. pneumoniae7,8,9. Neutrophils are not only important 
component of the innate immune system but also plays a key role in the regulation of adaptive 
immunity85,178,179. Neutrophils spearhead the host responses to pneumococcal pneumonia 
which results in an acute inflammation in the lung91,180. The important role of neutrophils 
during infections can be underscored when patients with neutrophil deficiencies such as 
neutropenia suffer from severe complications, which even lead to death181. Previous reports 
have also suggested that how neutrophil depletion can cause reduced clearance of S. 
pneumoniae91,92. Thus, if the neutrophils were functionally efficient, then the host would 
benefit from better bacterial clearance and in turn recovery. However, the transcriptional 
regulation for the proper functioning of neutrophils during pneumonia caused by S. 
pneumoniae remains poorly understood.  
7.1  In vitro 
In Fig. 9 and 10, it was demonstrated that both human and mouse neutrophils express KLF4 
when exposed to pneumococci indicating that KLF4 in neutrophils during S. pneumoniae may 
be of functional relevance. Since previous reports have suggested that KLF4 can be induced 
(by infection) in some other cells such as human lung epithelial cells136,167, human monocyte 
derived DCs182, BMMs163 and peritoneal mouse macrophages163,183, KLF4 may act as an 
important regulatory transcription factor in bacterial infections. Though the present study 
mainly involves a murine model, human blood neutrophils have also been used in the in vitro 
study to a) address the induction in genetic diverse mammals and b) humans. The induction of 
KLF4 was much more with the unencapsulated variant (R6x). In the previous in vitro studies, 
there was an induction of KLF4 in BMMs after stimulation with S. pneumoniae. Viable, 
replicating bacteria and released DNA are the responsible factors for the KLF4 induction in 
BMMs169. The thick polysaccharide capsule cover up the important components of the cell 
wall and this protects the bacteria against phagocytosis15. However, myeloid KLF4 deficiency 
did not alter phagocytosis of pneumococci (see below) in the experiments performed in this 
study. The capsule however prevents bacteria from being entangled in NETs15. KLF4 is 
spontaneously upregulated with Dachshund homolog 1 (DACH1) which in turn regulates 
cyclin dependent kinase (cdk) 4/6, a key machinery required for NETs formation184,185. Since 
a lower capsule content increases the chance of the bacteria being entangled in NETs which 
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may be influenced by KLF4 via the DACH1-cdk4/6 axis, this may be a postulated for the 
higher induction of KLF4 with the unencapsulated pneumococci. In addition, since 
unencapsulated pneumococci are responsible for more expression of KLF4 than encapsulated 
pneumococci, it can also state that the inducing factor for KLF4 is a pneumococcal cell wall 
component which is partly hidden by the capsule. 
Of note, the presented Western blots in Fig. 9 and 10 suggested that there was no KLF4 
induction at basal level which also has been reported at mRNA levels from other groups186. In 
contrary some groups have suggested that mouse bone marrow monocytic cells and peripheral 
blood monocytes express KLF4 at basal conditions162,183. In contrast to the increased 
induction of KLF4 with the unencapsulated pneumococci (as stated above) there was nearly 
no KLF4 induction when the cells were stimulated with pneumococci lacking the virulence 
factor autolysin (LytA) as given in Fig. 10. Further,  unlike in epithelial cells, there is no 
induction of KLF4 with bacterial DNA alone136 but the signal was partly back when the cells 
were stimulated with the combination of pneumococcal strain R6x∆lytA and bacterial DNA, 
the inducing factor for KLF4 in macrophages169. It has been reported that S. pneumoniae 
autolysin LytA (N-acetylmuramoyl-L-alanine amidase) activates immunomodulatory 
signaling pathways in macrophages by releasing bacterial cell wall constituents such as 
peptidoglycan and diconic acid187. Moreover, autolysis is important for the release of bacterial 
DNA188. The released DNA from pneumococci has also been stated to induce interferon-β 
(IFN-β) during infection189. Therefore, the expression of KLF4 in neutrophils is dependent on 
autolysis and may be partly on the release of bacterial DNA during the infection. 
Previous literature has suggested the recognition of S. pneumoniae is mediated among other 
receptors via Toll-like receptors (TLR2, probably TLR4 and TLR9)15,21,190,191,192. However, in 
the present study when neutrophils were stimulated with the TLR2 ligand MALP2 (as TLR2 
agonist) as given in Fig. 9B, there was no induction of KLF4 noted in human neutrophils. The 
pneumococcal cell wall components such as lipoteichoic acid and or lipoproteins are 
recognized by TLR2, which does not seem to have a role in KLF4 induction in neutrophils. 
Comparable observations have been reported by Taylor and colleagues, who demonstrated 
that the stimulation of embryonic stem cells with Pam3Cys, another TLR2 ligand, was not 
able to induce KLF4 expression193. 
In Fig. 9B, we also see that when neutrophils were stimulated with LPS as TLR4 agonist, 
there was no expression of KLF4. These results are in line with the findings of Liao et al. He 
and his coworkers had reported that LPS treated macrophages showed a reduction in KLF4 
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expression163. In contrast Liu et al. had pointed out the induction of KLF4 in macrophages 
after treatment with LPS194. The difference in finding may be because of the experimental 
setup: Liao et al. had used peritoneal macrophages and bone marrow derived macrophages 
from mice, Liu et al. had used macrophage cell line while the present study was done using 
human primary neutrophils. Additionally, Ply an important virulence factor of S. pneumoniae, 
released after autolysis may initiate inflammatory response through TLR415 but TLR4 seems 
not have a role in expression of KLF4 in human neutrophils in the present study.  
Human neutrophils were also stimulated with CpG as TLR9 agonist but there was no 
expression of KLF4 noted (see Fig. 9B). In contrast to epithelial cells, as given in Fig. 10 we 
have also seen that S. pneumoniae DNA as a TLR9 ligand was not able to induce KLF4 
(above) in mouse bone marrow neutrophils and human neutrophils. Thus, the partial induction 
of KLF4 by the bacterial DNA is rather independent of TLR9 but may be through an 
unknown receptor as it has previously been reported about the recognition of DNA by 
RAW264.7 macrophages via TLR9 and an unknown DNA sensor in the cell192. These data 
support a highly differentiated cell type–specific regulation of KLF4 expression and an 
underlying hitherto only partly know signaling pathway. 
The use of recombination systems such as Cre/loxP is a powerful tool for induction or 
suppression of genes in a cell/tissue specific manner in different mice models. With the 
conditional induction or suppression of the gene of interest, it helps us to find the cell specific 
role of that gene. The LyzMcre system was effective in ~90% knockdown in blood 
neutrophils (mature cells) but did not show any effect on immature neutrophils from the bone 
marrow or other WBCs as given in Fig. 11. The findings support the working principle of the 
LyzMcre system which states that it is effective only in mature myeloid cells and does not 
affect lymphocytes170.  
In the in vitro phagocytosis assay in Fig. 12, no differences in bacterial killing were observed 
between the KLF4-/- and KLF4+/+ mice. However, Liao et al. have previously reported that 
KLF4-deficient macrophages have enhanced bactericidal activity163. The difference in the 
outcome of the present findings may be because they used different bacteria (S. pneumoniae 
versus Staphylococcus aureus)163. In line with the observation in that study, Shen et al. have 
reported that bone marrow derived KLF4 KO neutrophils failed to kill E. coli166. S. 
pneumoniae initially interacts with the alveolar epithelial cells and the resident macrophages 
within the lung which in turn induces the chemotactic gradient for neutrophil sequestration at 
the site of infection91. Additionally report suggest that S. pneumoniae can reduce its capsule 
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content once it encounters airway epithelial cells20. Previous report have suggested that 
phagocytosis of S. pneumoniae by neutrophils is dependent on its capsule195. In all probable, 
the neutrophils, after sequestration to the site of inflammation, may interact with S. 
pneumoniae with low capsule content. Since we have already seen an increased KLF4 
expression with unencapsulated S. pneumoniae R6x in comparison to the wild type 
encapsulated S. pneumoniae strain D39 (see above), as a result, two different strains of S. 
pneumoniae have been used for the phagocytosis assay to assess the role of myeloid KLF4 
during phagocytosis with respect to bacterial capsule content.  
Unlike the bacterial killing, the KLF4-/- myeloid cells have a change in the cytokine profile in 
vitro as given in Fig. 13. In this study, it could be shown that KLF4-/- neutrophils have less 
pro-inflammatory cytokines such as TNF-and KC, 16h after stimulation with S. pneumoniae 
wildtype strain D39. The D39 strain have been used for the in vitro cytokine analysis because 
it has previously been reported that the capsulated variant of S. pneumoniae (D39) triggered 
much more cytokine response such as TNF-α, IL-6 and KC in comparison to the 
unencapsulated strain (D39Δcps). As a result, the capsule is needed for the early induction of 
cytokines196. Though the average life span of neutrophils in circulation is 8-12h but their life 
span greatly increases in the presence of pro-inflammatory mediators197. Additionally, 
Sangaletti et al. have co-cultured neutrophils isolated from mice along with myeloid DCs for 
16h198. The changes in pro-inflammatory cyto-/chemokine profile are in line with reports from 
Liu et al: they have reported that RAW264.7 macrophages express KLF4 and this expression 
of KLF4 regulates pro-inflammatory cytokines such as IL-1β194. Also, Feinberg and Kaushik 
et al. had previously hypothesized about the pro-inflammatory phenotype in myeloid cells 
such as macrophages and also in monocytic microglial cells165,199. Other studies have also 
provided insights into how KLF4 can fine-tune the inflammatory cytokines in different cell 
types. Tetreault et al. had observed KLF4 induces pro-inflammatory cytokines such as TNF-α 
and IL-1α via modulation of NF-κB in keratinocytes200. Another report had demonstrated that 
KLF4 is responsible of pro-inflammatory cytokines such as IL-6 in fibroblast-like 
synoviocytes of rheumatoid arthritis patients201. On the other hand, other groups have studied 
the anti-inflammatory role of KLF4. Hamik et al. for example, have shown that KLF4 confers 
anti-inflammatory phenotype in human umbilical vein endothelial cells by reducing pro-
inflammatory cytokine production such as IL-6 and C-reactive protein202. Another study had 
reported that KLF4 nullifies the induction of macrophage migration inhibitory factor (MIF) 
by transforming growth factor-β1 in renal tubular cells203. It is interesting to mention that MIF 
has been reported to be expressed in different cell types such as macrophages, PMNs and 
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epithelial cells204,205,206. This MIF is responsible for induction of pro-inflammatory cytokines 
such as TNF-α, IL-6, IL-1 from macrophages207. These data support a cell type–specific 
function of KLF4. In two different publications, Zahlten at al. have pointed out how KLF4 
can regulate the NF-κB pathway and in turn control the cytokine profile during S. pneumoniae 
induced pneumonia136,167 in human broncho-epithelial cells. While KLF4 is pro-inflammatory 
in myeloid cells as have been found in the present study and also has been reported earlier, 
whereas in the lung epithelial cells, loss of KLF4 during pneumococcal pneumonia enhanced 
pro-inflammatory cytokine response and reduced anti-inflammatory IL-10 secretion136,167. 
Taken together, the results point out towards a pro-inflammatory role of KLF4 in myeloid 
cells but an anti-inflammatory role in at least broncho-epithelial cells during pneumococcal 
pneumonia. Thus, it can be speculated that during bacterial pneumonia, KLF4 in myeloid 
cells and KLF4 in epithelial cells eliminates the pathogen and controls the inflammation 
respectively for maintenance of homeostasis. The in vitro findings are depicted in Fig. 21.  
 
Fig. 21 Pneumococci-dependent expression and function of KLF4 in neutrophils.  
The stimulation of neutrophils with MALP2 (TLR2 agonist), LPS (TLR4 agonist) and CpG (TLR9 agonist) did 
not induce KLF4 expression in neutrophils. However, bacterial (S.p.= Streptococcus pneumoniae) autolysis and 
bacterial DNA are at least in part responsible for KLF4 expression in neutrophils and this leads to production of 
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pro-inflammatory cytokines such as TNF-α and KC. It is also noteworthy that KLF4 has no impact on the 
phagocytic capability of the neutrophils on bacteria. 
7.2  In vivo 
After the identification of KLF4 over more than twenty years back208, further experiments had 
been done to assess the physiological role of this transcription factor. Genome wide KLF4 KO 
in mice has a lethal phenotype because of the lack of establishment of skin barrier156. As a 
result, there was a need for cell specific or organ specific KLF4 KO in mice to understand the 
tissue specific role of KLF4. Various models of KLF4 KO in a cell specific or organ specific 
manner have been used: for example, An et al. had demonstrated KLF4 KO in T cells to study 
T-cell development209. Yu et al. had used KLF4 KO lungs in murine model to study its role 
during lung cancer210. However, cell specific or organ specific KLF4 KO mice have rarely 
been used in bacterial infection model based on extensive literature review. One such model is 
used by Tussiwand et al. where they infected mice lacking KLF4 in cDCs with Citrobacter 
rodentium211. A recent study has also demonstrated the role of myeloid KLF4 KO during E. 
coli (a gram negative bacterium) infection166. In this E. coli induced sepsis mice model, it was 
shown that myeloid KLF4 has a pro-inflammatory phenotype. Myeloid KLF4 KO mice had 
higher bacterial burden with respect to WT mice, which was due to the lower pro-
inflammatory cytokine production by the myeloid cells after infection with E.coli. 
Consequently, there was less neutrophil recruitment in the KLF4 KO mice. Due to the higher 
bacterial load, there was higher mortality in KLF4 KO mice in comparison to the WT mice. 
The choice of animal model and the bacterial strain to be used for the in vivo study is an 
important consideration for experiments with pneumococcal pneumonia. Rat and rabbit 
models are uncommonly used in comparison to mice models. Among the mice models, 
various inbred strains such as BALB/c, C57BL/6 and CBA/J model have been used for 
studies in S. pneumoniae induced pneumonia. In principle, there are two ways in how the 
lungs in the mice can be infected-intratracheal or intra-/transnasal. The mice model used in 
the present study have always been infected transnasal, as the mode of infection intratracheal 
is complex and invasive technique. Additionally, another advantage of the transnasal 
application of pneumococci is that it mimics the natural way the pathogen enters the human 
system212. Another important decision is the choice of bacterial strain to be used for the in 
vivo study. The different strains have been used for in vitro and in vivo studies is based on 
literature review. The findings by Orihuela et al. suggested that in in vivo infection model, 
D39 (serotype 2) was responsible for high-grade sepsis while A66 (NCTC 7978, serotype 3) 
was responsible for development of pneumonia in mice213. The capsule is one of the most 
  
86 DISCUSSION 
important virulence factor of S. pneumoniae and the higher capsular content determines the 
immune responses during pneumococcal pneumonia. Serotype 3 was chosen for the in vivo 
model instead of the serotype 2 because the serotype 3 has much more thick capsule while the 
serotype 2 is lowly encapsulated20,214. Not only does the S. pneumoniae serotype contribute to 
the outcome of the disease but also the host genetic factors contribute to the outcome of 
bacterial pneumonia.  This is evident, based on different outcomes when different mice 
models are infected with the same S. pneumoniae strain215. Of the different types of mice 
model, serotype 3 strain has been commonly used for the C57BL/6 mice212. Taken together, 
the choice of animal model and the bacterial strain are important factors for studying 
pathogenesis of pneumonia.   
We could see in our model, a steep change in bacterial load in mice, deficient in KLF4 in the 
myeloid cells. KLF4-/- mice had higher bacterial load in the lungs, blood and in the spleen at 
24h post infection compared to the KLF4+/+ mice from the CFU experiments in Fig. 14, which 
is supported by a recent report166. In this publication, Shen et al. had reported higher bacterial 
load in the blood and peritoneal fluid of myeloid KLF4 KO mice with respect to WT mice in 
an E. coli sepsis model. The CFU result could be further ascertained when the whole lung 
samples for histology analysis were stained with S. pneumoniae antibody as given in Fig.14D. 
The results of this histology experiment revealed that KLF4-/- mice had 2 times the bacteria 
than KLF4+/+ mice. Overall, loss of myeloid KLF4 seem to impair the local limitation of 
bacterial growth and increase the risk of bacterial outgrowth. 
Infection of pneumococci in the lung in a murine model is associated with increased cytokine 
level in the BALF and recruitment of neutrophils with a concurrent growth of bacteria in the 
alveolar space between 4h to 24h post infection55. As a result, higher the bacterial load, higher 
cytokine level is expected. In spite of the higher bacterial load, KLF4-/- mice in the herein 
discussed experiments had lower pro-inflammatory cytokines and higher anti-inflammatory 
cytokine. KLF4-/- mice showed lower levels of pro-inflammatory cytokines such as TNF-α, 
IL-1β and chemokine such as KC while had increased anti-inflammatory cytokine such as IL-
10. The lower pro-inflammatory cytokines and enhanced anti-inflammatory cytokine was seen 
not only in the BALF but also in the plasma, 24h post infection as seen in Fig. 15 and 16 
respectively. The results support the hypothesis and by findings from Shen et al. which shows 
that pro-inflammatory factors such as myeloidperoxidase (MPO) and matrix metallopeptidase 
(MMP)-9 are produced to a less extent in the myeloid KLF4 KO mice during infection166. In 
addition, in vitro studies supported a potential pro-inflammatory phenotype of KLF4 positive 
cells in BMMs: KLF4 KO in BMMs decreased TNF-α, IL-1β, IL-6 while increased IL-10 
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production during pneumococcal pneumonia169. The low TNF-α in the BALF and plasma of 
the KLF4-/- mice in vivo may be because of the dual impact of KLF4 in the neutrophils and 
the BMMs (as seen from the in vitro experiments). Likewise, the less IL-1β and more IL-10 
production may be because of their regulations by KLF4 in BMMs. Additionally, the low KC 
production in the KLF4-/- mice can be correlated with the in vitro experiments where KC was 
not detectable in blood neutrophils (of KLF4-/- mice) on exposure to S. pneumoniae (see Fig. 
13). However Clausen et al. have also suggested that the LyzMcre is able to cause conditional 
gene knockout in CD11c+ splenic DCs170. It has previously been reported that human CD11c+ 
DCs shows increased cytokine levels during infection with pneumococci such as TNF-α, IL-
1β, IL-10, IL-8 (murine homolog: KC)216. Previous reports have also suggested that the 
LyzMcre was effective in knockdown of RelA protein from alveolar macrophages217. It has 
also been known that alveolar macrophages plays an anti-inflammatory role in the innate 
immune responses during pneumococcal pneumonia218. Whether KLF4 has any impact on the 
cytokine production of CD11C+ DCs and the alveolar macrophages during pneumococcal 
pneumonia needs to be addressed in further experiments.  
With the production of less cytokine, it was expected that there would have been less 
neutrophil recruitment in the BALF and in the plasma91,166. However, in the present study, a 
less neutrophil recruitment was seen only in the blood but not in the BALF as given in Fig. 
17. So what could be the reason that there were no differences in cell recruitment in the 
BALF? Mouse albumin ELISA was done to assess the vascular permeability within the lung. 
KLF4-/- mice showed an increased vascular permeability, which could be the reason that there 
are no changes in cell recruitment in the BALF, 24h after infection. It has earlier been 
reported that S. pneumoniae is responsible for increasing the vascular permeability within the 
lung176 and that this increased permeability is associated with intra-alveolar edema180. The 
findings from histopathology analysis revealed that KLF4-/- mice, 24h after infection showed 
significantly higher levels of perivascular edema and pleuritis. Experiments with human lung 
tissue indeed revealed that S. pneumoniae induces oxidative stress and extensive tissue 
damage219. Thus, the higher bacterial load may be responsible for disrupting the lung 
architecture (as seen in the enhanced vascular permeability) and this leads to a higher 
perivascular edema and pleuritis180,220. All this taken together can suggest that why there no 
differences in cell recruitment in the BALF between the KLF4-/- and KLF4+/+ mice. KLF4-/- 
mice also showed higher tendency of necrosis and more affected lung area in comparison to 
KLF4+/+ mice. It is noteworthy to mention that it has already been reported that S. 
pneumoniae is one of the causes of necrosis in the human lung221.  
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Sepsis is a condition in which infection in the blood can be documented222. From the blood 
CFU experiments, it was seen the S. pneumoniae could be detected in KLF4+/+ mice and to a 
significantly higher extent in the KLF4-/- mice. Therefore, the 24h time point could be 
considered as a stage where the mice just started entering the state of sepsis. Certain groups 
have already pointed out that S. pneumoniae affects the myocardium of the heart and is also 
associated with acute kidney injury (AKI)223,224. Additional reports have also suggested that S. 
pneumoniae is also responsible for meningitis and sometimes gastrointestinal 
infections49,50,225. The hypothesis was that the spread out bacteria from the lungs in the blood 
could affect other organs too. Various organs such brain, thymus, heart, liver, spleen, small 
intestine, large intestine and the kidneys were isolated from the mice and analyzed for 
histopathology. However, no such impact could be found on these above-mentioned organs. 
The differences is S. pneumoniae serotype strain could be the reason that the results could not 
be validated with reported literature. Previous report have suggested that of the 90 different 
serotypes of S. pneumoniae, some strains are more prone to nasopharyngeal colonization 
while other strains are responsible for invasive disease and spread into the blood stream. In 
this context, serotype 4 have been reported to have high level of invasiveness and can be 
detected to a large extent in the blood226,227,228. In the previous study, where S. pneumoniae 
could induce cardiac micro lesion, the study was done using TIGR4 (serotype 4 strain) while 
the present study is done using serotype 3 strain.  
When the progression of pneumonia was monitored over the period of 10 days, it was found 
that KLF4-/- mice had to be euthanized earlier in comparison to KLF4+/+ mice. There was a 
significant difference between the survival of KLF4-/- and KLF4+/+ mice. Various clinical 
symptoms associated with more sickness of KLF4-/- mice included raised fur, accelerated 
breathing rate and lower responses to external stimuli. As given in Fig. 20, it was seen that 
KLF4-/- mice had lower body temperature than KLF4+/+ mice as early as day 2. There was 
however no significant differences between the body weight of KLF4-/- and KLF4+/+ mice. 
The higher mortality of KLF4-/- mice in comparison to KLF4+/+ mice during S. pneumoniae 
induced pneumonia are in line with the findings from Shen et al.: they had reported earlier 
that KLF4 KO mice have lower survivability with respect to WT mice after infection with E. 
coli166. Previous reports have described that in order to understand the progression of 
pneumococcal pneumonia in a murine model, the mice have to be monitored 10 days after 
infection177,229. It has already been reported that various clinical symptoms associated with 
infection in mice include fall in body temperature, less responsiveness, dyspnea230. Taken 
  
89 DISCUSSION 
together, the loss of myeloid KLF4 reduce the chances of survivability during pneumococcal 
pneumonia. 
7.3 Concluding remarks 
From the in vitro experiments, it was revealed that KLF4 is not expressed in basal conditions 
but there was an induction of KLF4 in neutrophils during pneumococcal infection. The 
expression of KLF4 was much higher with the unencapsulated pneumococci than the 
encapsulated, suggesting that the component for KLF4 induction may be partly hidden by the 
capsule. However, this expression of KLF4 is independent of TLR2 and TLR4 so it may not 
be induced by lipoteichoic acid, lipoprotein or Ply. Additionally, this expression of KLF4 was 
reduced in pneumococci strain deficient in autolysin and not induced by bacterial DNA alone. 
However, the combination of bacterial DNA and autolysin-deficient S. pneumoniae strain 
could partly induce the expression of KLF4, suggesting the expression of KLF4 in neutrophils 
depends on autolysis and at least partly on the sequential release of bacterial DNA. The 
bacterial DNA is probably recognized through an unknown DNA receptor independent of or 
additionally to TLR9. Although KLF4 has no role in the phagocytosis by neutrophils but it 
can upregulate pro-inflammatory cytokines such as TNF-α and KC which might be through 
the regulation of NF-κB pathway as have been reported earlier 136,167.  
From the in vivo experiments it was found that KLF4-/- in myeloid cells led to higher bacterial 
load in the lung, blood, spleen of KLF4-/- mice with respect to KLF4+/+ 24h post infection. 
The higher bacterial load was due to less cytokine production such as TNF-α, IL-1β, KC in 
the BALF and in the plasma. Though there was less cell recruitment in the blood of KLF4-/- 
mice, yet there were no differences in the cell recruitment in the BALF between KLF4-/- and 
KLF4+/+ mice. The higher bacterial load in the KLF4-/- mice increased vascular permeability 
associated with perivascular edema, pleuritis and necrosis, which disrupted the lung 
architecture. The disrupted lung architecture allows the entry of non-functional myeloid cells, 
which cannot produce any cytokine (as seen in the in vitro data) for orchestrating the bacterial 
clearance. All this taken together could lead to an earlier onset of sepsis and an earlier death 
(euthanized) of KLF4-/- mice as seen from the survival data and clinical symptoms. The 
summary is shown in Fig. 22.  
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Fig. 22 Summary 
7.4  Outlook 
This study together with previous reports indicated that the transcription factor KLF4 must be 
considered as a major regulator of the (innate) immune response at least in pneumococcal 
pneumonia. As an outlook for the presented research project, in further studies, it should be 
investigated which pathways are responsible for the induction of KLF4 during bacterial 
pneumonia. The TLR data from this study should be verified by using e.g. neutrophils from 
TLR and other receptor (such as NLRs) KO mice. Deciphering the exact pathway through 
which KLF4 is expressed in neutrophils and how it can regulate the pro-inflammatory 
cytokine by acting directly on the NF-κB pathway or via other signaling pathways is also 
needed. This could be done for example by using chemical inhibitors of NF-κB-related 
pathways or knockdown experiments by siRNA, shRNA, CRISPR/Cas9 or other gene editing 
methods. Another important question is the impact of the different myeloid cells concerning 
the phenotype in the murine mouse model. To study this a transfer of isolated KLF4 KO cells 
(for example macrophages, neutrophils and DCs) in irradiated WT mice lacking immune cells 
could be done in future experiments. 
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This better understanding will help us develop novel therapies by targeting KLF4 as a central 
modulator of the inflammatory responses of myeloid cells during pneumococcal pneumonia. 
However, it should be noted that KLF4 is an important cell cycle regulator and also has been 
reported for its role in acute myeloid leukemia (AML) and therefore manipulation of myeloid 
KLF4 by e.g. adenoviral gene manipulation could bear the risk of the development of blood 
cancer231.  
Given that the research project is based on a murine model, the present study should be 
further investigated using pneumonia patient samples. There have been reports of differences 
in hematological parameters between human and mice232. Additionally, differences also exist 
between human and mice with respect to the innate and adaptive immune system74. As a 
result, neutrophils isolated from pneumococcal pneumonia patients should be checked for 
KLF4 expression in comparison to normal healthy subjects. The KLF4 expression in the 
neutrophils can be further correlated with chances of survival of the pneumonia patients. 
Given the poor outcome from extrapolation of rodent studies to humans233, various reports 
also suggest the use of human lung tissue as model for studying the pathophysiology of lung 
diseases234,235. Taken together, the human ex vivo lung model should be used along with the 
patient samples to validate the functional role of KLF4 during pneumococcal pneumonia in 
human subjects.  
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